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Heterotopic ossification (HO) is a pathological condition of abnormal bone formation in soft 
tissue. HO causes pain and restricts range of motion, greatly impairing functional mobility of the 
patient. Blast trauma-induced HO, in particular, has the highest incidence, and is the single most 
significant obstacle for combat-injured military personnel to return to active duty. Despite the 
clinical importance, the underlying mechanism of HO is poorly understood and effective 
treatment options are lacking.  
            This study aims to explore the cellular and molecular mechanism of blast trauma-induced 
HO. Using a live animal blast trauma model, we firstly showed that muscle trauma resulting 
from blast wave exposure is associated with HO formation. We then investigated the role of 
muscle injury in HO pathogenesis and showed that bone morphogenetic protein-7 (BMP-7) 
expression was highly upregulated following muscle injury. Inhibition of BMP-7 activity in vitro 
suppressed the osteogenesis-promoting effect of culture medium conditioned by injured muscle 
tissue on muscle-derived stromal cells (MDSCs), and in vivo reduced the volume of HO. These 
results indicate that BMP-7 is a key osteoinductive factor in injured muscle that facilitates HO 
formation. 
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Next, we sought to identify additional factors that could contribute to the pathogenesis of 
blast trauma-induced HO. We investigated the impact of glucocorticoids on HO formation since 
excessive endogenous glucocorticoid production due to stress is found in severe trauma patients. 
Our results showed that dexamethasone treatment together with cardiotoxin (CTX)-induced 
muscle injury led to a significant amount of dystrophic calcification (DC) in muscle. This effect 
was likely related to decreased circulating transforming growth factor-beta 1 (TGF-β1) level, as 
supplementation of recombinant TGF-β1 markedly rescued this phenomenon.  
Lastly, we investigated the involvement of muscle tissue death in HO pathogenesis. We 
observed that implantation of devitalized muscle tissue together with muscle injury induced by 
CTX injection caused DC formation, accompanied by a systemic effect of lowered circulating 
TGF-1 level.  
Taken together, these results strongly suggest that a two-hit mechanism of blast trauma-
induced HO, namely muscle injury-induced BMP-7 upregulation combined with pathological 
condition-induced downregulation of circulating TGF-1 level, is an important causative 
mechanism of DC/HO formation.  
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1.0  INTRODUCTION 
Heterotopic ossification (HO) is a pathological condition of abnormal bone formation in soft 
tissue [1]. Due to the mechanical effect of hard tissue inside soft tissue, HO usually causes pain 
and restricted range of motion [2]. HO can be generally divided into two broad categories: 
hereditary and acquired HO. Hereditary HO, also known as fibrodysplasia ossificans progressiva 
(FOP), is a rare autosomal dominant disease resulting from Activin A Receptor type I (ACVR1) 
gene mutation [3]. Acquired HO typically follows central nervous system (CNS) injury or direct 
musculoskeletal trauma [4]. However, the mechanism underlying the acquired HO is still 
unclear. Blast trauma-induced HO in particular, has the highest incidence among all types of HO. 
It has been shown to be the single most significant obstacle for combat-injured military 
personnel to return to active duty [5]. The goal of this study is to explore the cellular and 
molecular mechanism of blast trauma-induced HO. 
Chalmers et al. proposed that three factors were required to induce HO: (1) osteogenic 
precursor cells, (2) osteoinductive agents, and (3) an osteoconductive environment [6]. Since 
Urist’s landmark discovery of bone induction in skeletal muscle tissue by demineralized bone 
matrix [7], it is generally believed that skeletal muscle itself is a conductive environment for 
osteogenesis and that resident progenitor cells in skeletal muscle are capable of differentiating 
into osteoblast to form bone. However, little is known about the naturally occurring 
osteoinductive agents following trauma. Bone morphogenetic proteins (BMPs) have been the 
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most popular focus among the osteoinductive agents since their identification as the biologically 
active component(s) responsible for the osteoinductive capacity of demineralized bone matrix [8]. 
Previous investigations also suggest that the BMP signaling is normally active in muscle and is 
indispensable for muscle regeneration following injury [9, 10]. In this study, we have sought to 
explore if dysregulated BMP signaling is responsible for HO formation following muscle trauma, 
and what are the other factors that may work in concert with BMP signaling to cause aberrant 
osteogenesis. 
The introduction of the thesis will provide a review of the emerging findings regarding 
distinct types of HO to summarize the current understanding of HO mechanisms. In the 
experimental sections, focus will be first directed towards blast trauma-induced HO; specifically, 
we have shown in a live animal blast trauma model that muscle trauma resulted from blast wave 
exposure is associated with HO formation. The next part presents our findings on how muscle 
injury promotes HO formation in general. However, as muscle injury alone cannot cause HO, 
our next studies are concerned with investigating additional factors/pathological conditions that 
may contribute to the pathogenesis of blast trauma-induced HO. 
1.1 GENETIC HO 
The most common form of hereditary HO is FOP. Progressive osseous heteroplasia (POH) is 
excluded from this review given that it progresses from deep layers of skin to skeletal muscle 
thus might be different from typical HO [11]. 
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1.1.1 Clinical observations 
FOP is a life threatening disease and has an incidence of 1 in 2 million individuals [12]. Patients 
were born normal only with congenital malformation of the great toes. The extraskeletal 
ossification begins in childhood following flare-ups (painful soft tissue swelling), initiated by 
mild bodily trauma, such as childhood immunizations or play-related falls [12]. Progressive HO 
firstly forms around the trunk in affected patients (Figure 1), and then proceeds to the whole 
body [4]. Ectopic bone eventually spans the joints, which renders movements impossible. Most 
patients die of thoracic insufficiency syndrome at the age of around forty [12].  
 
Figure 1. Three-dimensional reconstructed computed tomography (CT) scan of the back of a twelve-year 
old FOP patient. Reprinted from reference [12] 
 
FOP is caused by a point mutation in the ACVR1 gene, which results in an amino acid 
change in codon 206 (R206H) in the glycine-serine (GS) activation domain of a BMP type I 
receptor, activin receptor-like kinase-2 (ALK2) [3]. The consequence of this R206H mutation is 
constitutive activation of BMP signaling, although the exact mechanism concerning how this 
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mutation perturbs BMP signaling is not totally clear. It is thought to be due to the altered binding 
of an inhibitory protein FKBP12 to GS domain that leads to constitutive activation of ALK2 [3]. 
1.1.2 Animal models 
To simulate human FOP condition, several transgenic mouse models incorporating ACVR1 gene 
mutation have been developed. The first constitutive active activin receptor-like kinase-2 
(caALK2) over-expression mouse model was developed with an artificial ligand-independent 
Q207D amino acid substitution at GS activation domain in ALK2 driven by a strong CAG 
promoter [13]. Further study has shown that induction of caALK2 expression by intramuscular 
injection of Cre-expressing adenovirus is sufficient to induce endochondral HO that phenocopies 
key aspects of human FOP, while global postnatal expression of caALK does not lead to HO 
[14]. Conditionally expressing caALK2 driven by nuclear factor associated T-cell 1 (Nfatc1) 
gene predisposes mouse to HO as early as P4 without antecedent injury, where HO happens most 
prominently in distal joints [15]. 
            The second more relevant transgenic mouse model was developed with the R206H 
mutation as it is identical to the ACVR1 gene mutation in human FOP [16]. Chimeric ACVR1 
R206H knock-in mice exhibited malformed digits and postnatal extraskeletal bone formation, 
recapitulating the phenotype of human disease [16]. However, ACVR1 R206H constitutive 
knock-in mice exhibited F1 generation lethality, which limits its utility in experimental studies 
[17]. Conditional ACVR1 R206H knock-in mice was then developed with a FlEx (flip-excision) 
system to allow ACVR1 R206H expression under control of the endogenous promoter [18]. Upon 
tamoxifen induction, the transgenic mice can develop HO in common ossification sites as they 
are in FOP patients without antecedent injury [18]. This study further showed that R206H driven 
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HO is a ligand-dependent process since BMP and activin ligand blockers (ACVR2A-Fc and 
ACVR2B-Fc) largely prevented HO from happening in these transgenic mice [18]. 
Based on the mechanism of FOP pathogenesis, BMP protein muscle implantation models 
and BMP over-expression transgenic mouse models have also been developed [19, 20]. Although 
non-physiological, these models still faithfully recapitulate the histological sequelae of HO 
development, i.e., tissue inflammation stage, fibroproliferation stage, chondrogenic stage, and 
osteogenic stage.  
1.1.3 Cellular and molecular mechanisms 
Based on the existing animal models, cellular and molecular mechanism leading to HO 
formation has been extensively studied. Earliest studies performed on BMP protein implantation 
model and BMP over-expression transgenic mouse model have identified that Tie-2 promoter 
driven Cre can label the majority of HO forming cells [19, 21]. Tie-2 is a receptor kinase for 
agiopoietin and is ubiquitously expressed in endothelial cells [22]. However, Tie-2 labeled cells 
are not necessarily endothelial cells given that Tie-2 positive cell population is distinct from VE-
Cadherin labeled endothelium [19], and injury dependent endothelial marker expression has also 
been observed in mesenchymal cells [23]. In these studies, Tie-2 lineage cells have been shown 
to be a population of fibro/adipogenic progenitors (FAPs) residing in the skeletal muscle 
interstitium [17]. They are multipotent mesenchymal progenitor cells which are positive for 
PDGFRα and Sca-1 surface makers [24]. They also have been shown to constitute a fraction of 
Scleraxis and Mx1 population [25, 26]. Therefore, targeting caALK2 to a Scleraxis and Mx1 
promoter driven Cre also largely mimics the effect of targeting it to Tie-2 promoter driven Cre 
[27]. 
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            In addition to the genetic aspect of the disease etiology, other interesting phenomena have 
been observed in FOP animal models as well as in ex vivo study of FOP patient samples, which 
shed light on the pathogenesis of FOP. First is that antecedent injury facilitates HO formation in 
mice either harboring caALK2 gene mutation or in mice with BMP-4 over-expression [16, 28]. 
Anti-inflammatory drug treatment and depletion of inflammatory cells typically inhibit HO 
formation in FOP animal models [14, 28, 29]. These findings indicate that tissue 
trauma/inflammation as the inducing event is required for HO development [30]. Recent study 
has examined proinflammatory and monocyte/macrophage changes in humans with FOP, and 
shown that there is a proinflammatory state caused by abnormal ALK2 [31]. Another study has 
demonstrated that FOP connective tissue progenitor cells respond to inflammatory signals 
through toll-like receptor (TLR), and ECSIT (Evolutionarily Conserved Signaling Intermediate 
in Toll Pathway) links TLR to BMP signaling [32]. This may suggest a possible link between the 
innate immune system and dysregulated BMP signaling in tissue progenitor cells. The second 
unexpected finding is that Activin A, usually acting as BMP signaling pathway inhibitory ligand, 
can activate caALK2 and its downstream Smad1/5 signaling pathway [18, 33]. Systemic 
inhibition of Activin A by its neutralizing antibody completely prevented spontaneous and 
injury-induced HO development in ACVR1 R206H knock-in mice, indicating a pivotal role of 
Activin ligand in inducing HO in FOP [18, 27]. Given that Activin plays a key role in the 
immune system, Activin could also mediate the cross-talk between Toll-like signaling pathway 
and BMP signaling pathway [34]. Other signaling pathways that are involved in the immune 
system, such as mTOR signaling [35], TGF-β signaling [36], hypoxia inducible factor-1α (HIF-
1α) signaling [37, 38] and retinoid signaling [39-41], have also been reported to affect HO 
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formation. However, the inter-relationship between these signaling pathways and BMP signaling 
pathway remains to be further explored. 
1.2 NEUROGENIC HO 
Neurogenic HO (NHO) is defined as HO following spinal cord injury (SCI) and traumatic brain 
injury (TBI) [42]. 
1.2.1 Clinical observations 
The incidence for NHO following CNS injury has been reported to be 1 in 5 patients [43]. 
Ectopic bone formation begins within 2 months after neurologic injury and usually forms around 
large joints (Figure 2) [44]. It has also been reported that many patients with head injury have 
accelerated fracture healing, which has been considered as a variant of NHO [45]. In some 
circumstances, injury to peripheral nerve could also compromise CNS integrity [46]. It is still 
unclear whether HO in elbow and hip joint is the result of damage to ulnar nerve and sciatic 
nerve. Risk factors for neurogenic HO include: artificial ventilation, immobilization, and 
muscular spasticity [42]. Specifically, artificial ventilation alters blood homeostasis of 
electrolytes and acid-base balance, both of which will affect osteogenesis [45]. Immobilization 
and muscular spasticity have been suggested as a cause of increased risk of muscle tears from 
active or passive movement [47]. Current prophylaxis and treatment for NHO include: 
nonsteroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, radiation therapy and surgery 
[48]. 
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Figure 2. X-ray image of HO formed around the knee joint of a patient with paraplegia. Reprinted from 
reference [44], License Number 4685550963219 
 
The etiology of NHO is incompletely understood. Central hypothesis for the pathogenesis 
of NHO is the release of osteogenic humoral factors following the breakdown of blood-brain 
barrier [49]. In vitro studies support this notion by demonstrating that the cerebrospinal fluid 
(CSF) and serum from patients with severe TBI have an osteoinductive effect and are able to 
stimulate cell proliferation [50-52]. Neuroinflammation has also been implicated in NHO [53]. 
Neuroinflammation refers to a process in which CNS injury triggers inflammatory reactions in 
peripheral tissue through the release of substances from the peripheral terminals of peptidergic, 
sensory nerve fibers [54]. Indeed, the neural-inflammatory factor substance P (SP) has been 
found dramatically increased in NHO lesions [55] and in the plasma of NHO patients [56]. In 
addition, conditioned medium derived from activated CD14+ monocytes/macrophages isolated 
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from NHO lesion strongly stimulated the mineralization of muscle-derived stromal cells 
(MDSCs) isolated from the same place [57].  
1.2.2 Animal models  
The first and only mouse model of NHO was developed by a combined thoracic spinal cord 
transection and local muscular trauma [56]. NHO developed in the muscle injury site; 
mineralization was evident on CT scans as early as 3 days after injury [56]. The development of 
NHO was independent of paraplegia associated with SCI since non-paralyzed front limb also 
developed HO following local muscular trauma [56]. Further research done by the same group 
showed that peripheral denervation increased HO volume on the original model, and peripheral 
denervation alone without SCI could also induce HO in about 50% of mice with local muscular 
injury [58]. 
1.2.3 Cellular and molecular mechanisms 
In the above mentioned mouse NHO model, the research group tested several cell lineages 
derived from muscle tissue and showed that muscle satellite cells (D45-Ter119-CD31-Sca1-
CD34+), interstitial cells (CD45-Ter119-CD31-Sca1+CD34+) and muscle progenitor cells 
(CD45-Ter119-CD31-Sca1-CD34-) could all mineralize in vitro to the same extent as 
mesenchymal progenitor cells derived from bone marrow [56]. They also showed that muscle 
interstitial cells underwent osteoblastic differentiation in response to plasma derived NHO mice 
without additional osteogenic stimuli, suggesting that progenitor cells in the muscle could be the 
cell source for NHO [56]. Other studies speculate that progenitor cells that reside in 
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endoneurium of peripheral sensory nerves give rise to NHO given that many cells positive for 
osterix, an osteogenic marker gene, can be found in nerve during bone formation process [59-61]. 
Furthermore, depletion of macrophages by clodronate-loaded liposomes reduced the size of 
NHO by 90%, indicating the participation of inflammatory cells in NHO as well [56]. 
Recently, Oncostatin M (OSM) has been found to be the coupling factor linking 
macrophages with MDSCs, which is indispensable for NHO development [57]. Data supporting 
this notion are as follows. OSM level significantly increased in plasma of NHO patients 
compared to healthy controls. Treatment with OSM neutralizing antibody greatly reduced the 
osteogenesis stimulating effect of conditioned medium derived from activated CD14+ 
monocytes/macrophages isolated from NHO lesion. Mice that are deficient for OSM receptor 
had significantly reduced HO volume compared to WT control after SCI and local muscular 
trauma. However, since depletion of OSM receptor did not achieve the same effect with 
depletion of macrophages, other factors linking macrophages with MDSCs should also exist and 
have yet to be explored.  
Several earlier studies also indicate that SP is indispensable for BMP-induced HO 
formation [55], and SP delivery could induce HO with up-regulated BMP-2 expression in mouse 
tendon [62]. SP acts on mast cells via binding to neurokinin 1 receptor (NK1r), which induces 
mast cell degranulation and release of numerous pro-inflammatory factors [60]. Studies showed 
that in animals lacking functional sensory neurons or in null mutation of SP gene animals, BMP-
induced HO was dramatically inhibited [55, 60]. Inhibition of mast cell degranulation or in mast 
cell deficient mouse line, HO was dramatically reduced as well [55, 60]. In summary, these data 
collectively suggest that there is a potent neuro-inflammatory circuit contributing to BMP-
induced HO formation. 
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1.3 TRAUMATIC HO 
The following part will review the literature of traumatic HO with special focus on blast trauma-
induced HO.  
1.3.1 Clinical observations 
Traumatic HO is typically considered as HO triggered solely by injury, most often following 
extensive soft tissue injury [63]. The rate for HO happening following distal humerus fractures is 
about 8.6%, elbow fractures about 5.5-18.8% [64]. The rate can reach to 90% following 
acetabular fractures and total hip arthroplasty (THA) (Figure 3) [65]. The severity of post-THA 
HO is assessed using the Brooker classification system [66]. Radiographic HO may be apparent 
2 weeks after surgery and reaches fully mature around 3 months [67]. Sex, surgical approach, 
and implant type have large effects on HO incidence [68]. HO happening subsequent to thermal 
injury ranges from 0.2% to 4%, with elbow being the most affected site [69]. The risk factors for 
developing HO after burn injury include: greater burn size, greater burn depth, longer period of 
immobilization [69]. Current prophylaxis for traumatic HO include radiation therapy and 
NSAIDs treatment [70]. However, the treatments and preventive measures are contingent upon 
the severity of the trauma. Use of bisphosphonates can prevent mineralization and is 
advantageous for treating bone loss caused by metabolic changes following burn injury [71].  
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Figure 3. X-ray image of HO following THA surgery. Reprinted from reference [44], License Number 
4685550963219 
 
The highest rate of HO happens in combat-related blast injuries, the prevalence of which 
is reported to be 64.6% in high-energy wartime extremity wounds during Operation Enduring 
Freedom and Operation Iraqi Freedom [72]. HO can cause significant pain and functional 
immobility when it forms adjacent to neurovascular structures and joint structures (Figure 4). HO 
can be evident on radiographs less than two months after the initial injury, and is not very likely 
to develop after this two-month period has passed [73]. In these war-wounded patients, TBI, age 
of less than thirty years, an amputation, and multiple extremity injuries with an Injury Severity 
Score ≥16 are regarded as risk factors for HO development [72]. The number of debridement 
procedures and the longer duration of negative-pressure wound therapy are also positively 
correlated with HO development, but they are more likely to be an indicator of the severity of 
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local injury rather than an independent indicator for development of HO [72]. In another cohort 
of amputees, a final amputation level within the zone of injury and a blast mechanism are 
considered as risk factors for HO development [73]. Common prophylaxis measures of HO are 
usually restrictive in blast injury patients, either because of other complications of the patients or 
logistical barriers that prevent the employment of these treatments [5]. Symptomatic HO can be 
managed with conservative therapies, such as rest, pain medication, physical therapy, and socket 
modification for amputees [74]. Fortunately, only 6.7% patients need surgical excision due to 
persistent symptoms [73]. 
 
Figure 4. Radiograph showing severe HO in amputated limb of blast-injured patient. Reprinted from 
reference [74], License Number 4685560368540 
 
The mechanism for traumatic HO remains unclear. It can be considered as a condition of 
pathological wound healing [75], which involves both local and systemic inflammatory reactions 
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[76]. Studies have confirmed that there is a hyper-inflammatory local and systemic response in 
patients who developed HO compared with those who did not, which is associated with elevated 
injury severity score, bacterial wound colonization and eventually wound failure [77, 78]. A 
proposed theory for HO development is that progenitor cells induced by this imbalance in local 
and systemic factors following traumatic injury undergo osteogenic differentiation to form HO 
[74, 79]. Our laboratory has previously identified and characterized a population of muscle 
resident mesenchymal progenitor cells (MPCs) derived from wound debridement of blast 
trauma-injured patients who later developed HO [80-82]. This cell population is capable of tri-
lineage differentiation, a characteristic of adult mesenchymal stem cells (MSCs), expresses MSC 
lineage markers, and also exhibits trophic properties that are associated with MSCs [83-86]. 
Davis et al. further showed that this cell population was found in greater number in muscle 
biopsies of patients with subsequent HO, suggesting its potential role as cell source for HO [87]. 
At the tissue level, osteogenic maker genes were up-regulated in wounds in which HO developed 
compared with wounds in which HO did not [88]. Further studies are needed to identify the pro-
osteogenic factors in traumatized muscle and to investigate how they interact with muscle 
progenitor cells to initiate HO formation [34]. 
1.3.2 Animal models 
The most widely studied animal model for traumatic HO is Achilles tenotomy with burn injury 
model [89]. Specifically, mice received Achilles tenotomy and 30% dorsal surface area burn for 
18 seconds with a 60℃ heated metal brand. Mice that underwent Achilles tenotomy alone 
develop HO in calf muscle through an endochondral ossification process 10 weeks post trauma 
[90]. Concurrent dorsal burn injury enhanced HO growth in calf muscle and Achilles tenotomy 
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site [91]. Burn injury also enhanced HO formation in BMP-induced HO model [92]. HO growth 
and development was attenuated when Achilles tenotomy and burn injury were performed on 
immunocompromised mice [93]. 
The first blast trauma HO model was developed by Tannous et al. using real explosive 
placed inside a water tank [94]. Rats were placed on a platform above the water with a hole only 
exposing the animal's hind limb to the water column caused by detonation. They showed that 
100% of rats subjected to this extremity blast hind limb amputation model developed HO in 4 
weeks in the absence of additional exogenous osteogenic stimulus [94]. They further 
demonstrated that a sand blasting medium could also induce HO, suggesting that the blast 
mechanism induces HO regardless of the blast medium [95]. The second model of this kind was 
developed by Polfer et al. using a blast tube capable of producing a blast overpressure at 120 kPa 
[96]. They showed that blast overpressure plus severe extremity trauma was able to create HO in 
100% of the experimental rats in 2 weeks. In this study, they also pointed out that blast 
overpressure alone was not able to induce HO, but severe extremity trauma alone created HO in 
about 60% of the experimental animals [96]. In another study, they further introduced bacterial 
colonization into this model, and found increased HO volume which may due to the chronic soft 
tissue inflammation [97]. 
1.3.3 Cellular and molecular mechanisms 
Earliest studies performed on Achilles tenotomy model have reported that cells forming 
traumatic HO are from the paired related homeobox 1 (Prx-1) lineage [37]. Later studies showed 
that Scleraxis lineage (Scx) cells contributed to each stage of traumatic HO anlagen [26]. It is 
highly likely that cells from both lineages are PDGFRα and Sca-1 positive multipotent 
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mesenchymal progenitor cells which constitute a fraction of the Prx-1 and Scx population [25]. It 
is also possible that endothelial-to-mesenchymal transition (EndMT) to serve as a mechanism to 
produce the PDGFRα positive cell source to HO lesion [23]. 
Studies have shown that modulation of Smad1/5/8 phosphorylation with either small 
molecule inhibitor targeting BMP type I receptor kinase activity or drugs that promote ATP 
hydrolysis could mitigate traumatic HO formation resulting from Achilles tenotomy [91]. 
However, unlike genetic HO which is caused by mutation in ALK2 hyperactivity, all BMP type I 
receptors (ALK2, ALK3, ALK6) are likely involved in traumatic HO pathogenesis, given that 
knocking out any single receptor cannot inhibit HO formation [75]. Same with genetic HO, 
mTOR signaling [37, 98], TGF-β signaling [99], and HIF-1α signaling [37] also affects HO 
formation following Achilles tenotomy.  
Molecular and histological analysis of HO progression in blast trauma-induced HO 
model confirmed its endochondral ossification nature [100]. Therefore, drugs modulating tissue 
inflammation stage, fibroproliferation stage, chondrogenic stage, and osteogenic stage should all 
affect HO formation. In line with this, Vancomycin treatment [101], Palovarotene treatment [102, 
103], and Rapamycin treatment [104] all could suppress HO formation, probably through a 
combined effect of modulation of systemic inflammation, progenitor cell proliferation and 
chondrogenesis.  
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2.0  DEVELOPMENT OF A NOVEL MOUSE MODEL OF BLAST TRAUMA-
INDUCED HO 
2.1 INTRODUCTION 
Blast injury is a complex type of physical trauma resulting from the exposure to an explosion. 
The unique injury pattern of blast injury is comprised of primary injury caused by blast wave 
itself, secondary injury caused by missiles being propelled by the blast force, tertiary injury due 
to impact with another object, and quaternary injury such as burn injury due to heat dissipated 
from explosive etc. [105]. Blast injury sets it apart from civilian trauma, given that a polytrauma 
comprised of soft tissue injury, CNS injury, open fracture, foreign body and bacterial 
contamination, and burn injury is seldom seen outside the battlefield  [106]. This multifaceted 
injury pattern may account for the highest rate of HO happening following blast trauma, since 
CNS injury and burn injury have already been shown to increase the chances of HO development. 
However, given that HO was not a common occurrence in previous wars but had an increased 
prevalence in modern wars since higher order explosive has been used [74], we postulate that 
high-energy extremity trauma caused by supersonic blast wave plays a dominant role in driving 
HO formation.  
In this part of the thesis, we report the employment of a blast device to test the direct 
effect of blast wave exposure on HO pathogenesis. The device was constructed based upon a 
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previously reported design used to test the effects of blast waves on internal organs [107], which 
was able to produce a supersonic blast wave comprised only of air. By using this blast device, we 
have demonstrated that blast wave exposure is sufficient stimulus for induction of HO, and 
muscle trauma resulted from blast wave exposure is associated with HO formation.  
2.2 METHODS 
2.2.1 Blast device 
A blast device was constructed based on a design described previously (Figure 5) [107]. Briefly, 
a 3,500 psi compressed nitrogen cylinder was used to charge a 150 mL air storage chamber. 
Using a solenoid control system, the stored air was allowed to discharge to the blast nozzle. A 
rupture disc (OSECO, Broken Arrow, OK) at the base of the blast nozzle would burst at 1,850 
psi, generating a blast wave emitting from the base of the nozzle. Theoretically, a burst pressure 
of 1,850 psi at 1 inch above the specimen platform should deliver an estimated 530 m/s blast 
wave reaching the tissue. The distance between the nozzle and the specimen platform could 
determine the force of the blast wave.  
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Figure 5. Schematic of the blast device 
2.2.2 Blast-amputation procedure 
Using an IACUC-approved protocol, 8-12 week old male C57BL/6J mice (Jackson laboratory) 
were first anesthetized by Isoflurane inhalation. The right hind limb was then removed of hair 
and was sterilized broadly with Povidone-iodine. The animal was positioned onto the operative 
field with a protective shield placed over the body, and only the right hind limb was left outside 
to be exposed to the blast wave (Figure 6). The animal was positioned so that the right hind limb 
knee was centered below the blast nozzle. Immediately following the blast, an above-knee 
amputation was performed. In cases of substantial bleeding, handheld thermal cautery was used 
to obtain hemostasis. Wound was closed in layer. Muscular compartments were closed over the 
residual limb with 4-0 vicryl sutures. Skin was closed with 4-0 nylon sutures. Prophylactic 
antibiotics (100 mg/kg ampicilin) were administered one-time at the end of surgery. The animal 
was allowed to recover under a heat lamp until ambulating about the cage, and received a 3-day 
course of buprenorphine (0.05 mg/kg administered subcutaneously twice a day) for pain 
management.  
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Figure 6. Blast-amputation procedure 
(A) Animal was deeply anesthetized. (B) The body of animal was protected, only the right hind limb was left outside 
the shield to be exposed to the blast wave. (C) Severe extremity trauma was seen following blast injury. (D) Animal 
underwent above-knee amputation and wound closure. 
2.2.3 HO formation assessment 
Blast-injured mice were harvested for different time points for microCT and histology analysis 
of HO formation. A Scanco vivaCT 40 scanner (Brüttisellen, Switzerland) was used for all 
microCT image acquisition. Scans were acquired at 45 kVp, 88 A, 300 ms integration time and 
at an isotropic voxel size of 35 m. Following micoCT imaging, muscle tissues were isolated 
from the animal and fixed in methanol overnight. Muscle tissues were then paraffin embedded 
and sectioned. H&E staining and Alizarin Red staining were performed to visualize tissue 
structure and calcium deposition. 
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2.3 RESULTS 
2.3.1 Characterization of blast trauma-induced HO 
Radiographic evidence of HO formation was observed at 4 weeks post blast injury (Figure 7A). 
Histology revealed that it was mature bone formation with lamellar bone and bone marrow 
cavity (Figure 7C&D). Red blood cells were also observed in HO lesion, indicating active 
hematopoiesis. From serial sections, we found that isolated HO grew inside the muscle fibers and 
had a size of approximately 300 m sphere. Interestingly, HO is always located proximal to the 
amputation site and distant from the femur, which is quite different from periosteal reaction that 
we have observed adjacent to the fractured femur. 
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Figure 7. Characterization of blast trauma-induced HO 
(A) Representative microCT image showing HO (arrowhead) in muscle. (B) Diagram providing orientation for 
microCT. (C) H&E staining showing mature HO in muscle. (D) Alizarin Red staining demonstrating calcium 
deposition. Scale bar = 200 m 
2.3.2 Muscle trauma is associated with HO formation 
To determine the time course of HO progression, we harvested muscle tissue 3 days, 7 days, 14 
day and 28 days post blast injury. H&E staining revealed that muscle tissue was severely 
damaged at early time points with inflammatory cell infiltration (Figure 8A&B). In 2 weeks, 
dystrophic calcification (DC) was found within regenerated muscle fibers (Figure 8C), and 
mature bone structure was found in 4 weeks (Figure 8D). 
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Figure 8. Time course of HO progression 
H&E staining illustrating HO progression: (A) 3 day post blast injury (B) 7 day post injury (C) 14 day post injury 
(D) 28 day post injury. Scale bar = 200 m 
2.4 DISCUSSION AND CONCLUSION 
In this part of the thesis work, we have successfully developed a novel mouse model of blast 
trauma-induced HO. We showed mature bone formation in the hind limb muscle 4 weeks 
following blast wave exposure to the mouse extremity. We demonstrated that HO formation is 
independent of exposure to heat and chemical residue from the explosive, since we employed a 
blast device that produces a supersonic blast wave comprised only of air. We largely ruled out 
the effects of CNS injury, foreign body and bacterial contamination on HO pathogenesis, given 
that the body of the animal was protected from being exposed to the blast wave and the operation 
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was performed under aseptic condition. Therefore, we concluded that blast wave exposure is 
sufficient stimulus for induction of HO in residual limb. 
The progression of HO seemed to be through DC directly towards mature lamellar bone 
formation. Cartilaginous precursor stage typical of endochondral ossification was not as readily 
evident in HO lesions. Recent study has reported that the transition from calcification to 
ossification may be stages of a pathologic continuum [108]. In other words, persistent DC in 
skeletal muscle is sufficient to drive HO formation. This discovery may uncover a potential new 
paradigm in HO pathogenesis, which seems to bypass the classical fibroproliferative stage and 
cartilaginous stage of endochondral bone formation. Our data support this postulation by 
showing that a DC precursor stage may initiate HO formation. We also demonstrated that severe 
muscular trauma precedes the formation of DC. In the next chapter, role of muscle injury in HO 
pathogenesis will be further explored to delineate the whole picture of this pathologic condition. 
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3.0  ROLE OF MUSLCE INJURY IN HO PATHOGENESIS 
Chapter 3 is adapted from a published article in Journal of Orthopaedic Translation 
Li L., Jiang Y., Lin H., Shen H., Sohn J., Alexander P.G., Tuan R.S.. Muscle injury promotes 
heterotopic ossification by stimulating local bone morphogenetic protein-7 production. J Orthop 
Translat, 2019. 18:142-153. 
3.1 INTRODUCTION 
As mentioned above, different types of HO do not utilize identical mechanistic pathways of 
pathogenesis. However, muscle injury appears to be a unifying feature for all types of HO. In 
FOP patients, low levels of muscular trauma following childhood immunizations or play-related 
falls can result in HO [12]. In neurogenic HO, microtrauma to muscles resulting from forced 
passive movements following a period of immobilization will lead to an increased risk of HO 
[47]. In traumatic HO, more severe levels of muscular trauma, as in cases of arthroplasty and 
blast trauma, can lead to an HO incidence of 20% and 64.6%, respectively [72, 109]. Muscle 
injury usually incurs an inflammatory response, and anti-inflammatory drugs have been used as 
prophylaxis in HO-susceptible patients [43]. However, the precise mechanism by which muscle 
injury facilitates HO formation and the mechanistic rationale for the use of anti-inflammatory 
drugs in the prevention of HO are still largely unknown.  
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In experimental animal HO models, cardiotoxin (CTX) injection has been commonly 
used to induce muscle injury and subsequent HO. CTX belongs to the family of snake venom 
polypeptide toxins that cause depolarization and contraction of muscle fibers [110]. Eventually, 
CTX causes muscle degeneration through myocyte death, which subsequently elicits a 
regenerative response thought to be mediated by infiltrating inflammatory cells [111]. CTX has 
been widely used in a large number of mouse HO models, such as the BMP-4 over-expression 
HO model [21, 28], constitutively active Activin receptor-like kinase-2 (caALK2) HO model [16, 
25, 26, 55], spinal cord injury neurogenic HO model [56], plasminogen deficiency HO model 
[112], and the burn injury HO model [113]. Similar to human HO conditions, muscle injury 
seems to be indispensable for HO development in these experimental animal models. However, 
given the importance of muscle injury in HO pathogenesis, it is striking that few studies have 
justified the usage of CTX and explained by which mechanisms CTX-induced muscle injury 
facilitates HO formation. 
This study examines the underlying cellular and molecular mechanisms linking muscle 
injury to HO by using CTX to induce muscle injury in a BMP-2-induced HO mouse model. We 
hypothesized that soluble, pro-osteogenesis factors present in damaged muscle tissue are able to 
push muscle-derived stromal cells (MDSCs) towards osteoblastic differentiation to facilitate HO 
formation. In this study, we sought to identify the osteoinductive factors actively involved in this 
process, thus providing a general mechanism by which muscle injury facilitates HO formation. 
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3.2 METHODS 
3.2.1 In vivo induction of HO 
Using a protocol approved by the Institutional Animal Care and Use Committee (IACUC), the 
calf muscle of the right leg of 8-12 week old male C57BL/6J mice (Jackson laboratory, Bar 
Harbor, ME, USA) were first injected with 50 L of 10 M CTX (Calbiochem, San Diego, CA, 
USA). One day later, the calf muscles of both legs were injected with 0.5 g BMP-2 (R&D 
Systems, Minneapolis, MN, USA) encapsulated in 50 L photocrosslinked methacrylated 8% 
(w/v) gelatin hydrogel scaffold developed in our laboratory [114]. Two weeks later, mice were 
euthanized for imaging by microCT (Scanco Medical vivaCT 40, Brüttisellen, Switzerland) to 
detect HO formation. Scans were acquired at 45 kVp, 88 A, 300 ms integration time and at an 
isotropic voxel size of 35 m. Bone density was calculated as mg hydroxyapatite (HA)/volume 
(cubic centimeter, ccm). 
A separate group of mice were subcutaneously injected with 1 mg/kg dexamethasone 
daily (Vedco Inc., Saint Joseph, MO, USA) for seven days following CTX and BMP-2 injection 
to suppress inflammation. Two weeks later, mice were euthanized for microCT analysis of HO 
formation. 
3.2.2 CTX-injured muscle tissue sample collection 
CTX injection alone group was performed as follows. The calf muscles of both legs of C57BL/6J 
mice were injected with CTX as described above. At different time points, mice were sacrificed 
and calf muscles from left and right sides were immediately harvested and snap-frozen in liquid 
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nitrogen for later muscle tissue RNA and protein isolation respectively. Uninjected mice served 
as Day 0 control.  
A separate group of mice were used for muscle tissue derived conditioned medium 
collection. The calf muscle of the right leg of C57BL/6J mice was injected with CTX as 
described above. On day 2, mice were sacrificed and the calf muscles of both legs were 
processed as follows. Briefly, pooled muscle tissue samples (1 g) from either the control left leg 
or the CTX-injured right leg were cut into 3-mm pieces and cultured in 10 mL growth medium 
(GM, high-glucose Dulbecco’s Modiﬁed Eagle’s Medium [Gibco, Gaithersburg, MD, USA] 
supplemented with 20% fetal bovine serum [Gemini Bio Product, West Sacramento, CA, USA] 
and 1% penicillin/streptomycin [Gibco]). Conditioned medium (CM) was changed and collected 
every day for three days and stored at -80℃ for later use.  
3.2.3 In vitro osteogenesis induction with muscle tissue derived conditioned medium 
CM derived from CTX-injured muscle tissue (CTX CM) and CM derived from control muscle 
tissue (CTL CM) were used to culture MDSCs at a dilution of 1:2 in GM for three days. MDSCs 
were harvested from another cohort of mice according to a previously described protocol [115]. 
On culture day 3, MDSCs were collected either for quantitative real-time reverse-transcription 
polymerase chain reaction (qRT-PCR) analysis or Western blot analysis. PCR data and Western 
blot data were normalized to MDSCs cultured in GM only. 
For inhibition of BMP-7 in vitro, MDSCs were maintained for three days in GM or 
muscle tissue derived CM with the supplementation of either 1 g/mL BMP-7 neutralizing 
antibody (ab27569, abcam, Cambridge, MA, USA) or 1 g/mL isotype control antibody 
(ab171870, abcam). On culture day 3, MDSCs were collected either for measurement of alkaline 
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phosphatase activity using an Alkaline Phosphatase Assay kit (ab83369, abcam) or 
phosphorylated Smad1 level using a SMAD1 (pS463/S465) ELISA Kit (ab186036, abcam). For 
the phosphorylated Smad1 ELISA, protein was extracted 1 hour after the change of day 3 CM. 
3.2.4 qRT-PCR analysis 
Tissues or cells were lysed in QIAzol Lysis Reagent and isolated using the RNeasy Mini Kit 
according to the manufacturer’s instructions (QIAGEN, Hilden, Germany). RNA was then 
converted to cDNA using the SuperScript™ IV First-Strand Synthesis System (Invitrogen, 
Carlsbad, CA, USA). Quantitative real-time PCR was performed with a StepOne Plus Realtime 
PCR system using PowerUp™ SYBR® Green Master Mix (Applied Biosystems, Foster City, 
CA, USA). The relative level of gene expression was calculated using the 2-delta delta Ct 
method. Primer sequences for actin, runt-related transcription factor 2 (Runx2), osterix (OSX), 
alkaline phosphatase (ALP), bone sialoprotein I (BSP-1), BMPRIA, BMPRIB, and ACVR1 are 
listed in Table 1.  
3.2.5 Western blot 
Total protein from tissues or cells was extracted using lysis buffer provided in the 
phosphorylated Smad1 ELISA kit. Protein concentration was determined using the bicinchoninic 
acid assay (ThermoFisher Scientific, Waltham, MA, USA), and equal loads of reduced protein 
samples were electrophoretically separated on NuPAGETM 4-12% Bis-Tris Gel (Invitrogen) and 
then transferred to a PVDF membrane using iBlot Dry Blotting System (Invitrogen). Primary 
antibodies directed against BMP-2 (ab14933, abcam), BMP-4 (ab39973, abcam), BMP-7 
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(ab56023, abcam), BMP-9 (ab35088, abcam), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) (CST5174, Cell Signaling Technology, Danvers, MA, USA), total Smad1 (CST6944, 
Cell Signaling Technology) and phosphorylated Smad1/5 (CST9516, Cell Signaling 
Technology) were incubated at 4℃ overnight, followed by horseradish peroxidase-conjugated 
secondary antibody (GE Healthcare Life Sciences, Marlborough, MA, USA) incubation. Western 
blots were developed using SuperSignal™ West Dura Extended Duration Substrate 
(ThermoFisher Scientific), and visualized using a FOTO/Analyst1 Fx CCD imaging system 
(Fotodyne, Hartland, WI, USA). 
3.2.6 Histology and immunostaining  
Muscle tissues were fixed in methanol and paraffin embedded. For histology, sections (9 m 
thick) were collected on Colorfrost Plus microscope slides (ThermoFisher Scientific), rehydrated, 
and H&E staining was performed according to a routine Harris Hematoxylin and Eosin protocol. 
Immunohistochemistry (IHC) was performed according to protocols described for the Vectastain 
Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA). Images were taken using a CKX41 
microscope (Olympus, Tokyo, Japan) equipped with a DFC 3200 camera (Leica, Wetzlar, 
Germany). For immunofluorescence staining, tissue sections were blocked in 10% bovine serum 
albumin for 20 minutes, then incubated overnight at 4℃ with mixed primary antibodies against 
BMP-7 (ab56023, abcam) and CD68 (ab53444, abcam). On the second day, sections were 
incubated with mixed secondary antibodies against rabbit IgG (ab150077, abcam) and rat IgG 
(ab150158, abcam) at room temperature for 1 hour. After washing, the slides were mounted with 
4′,6-diamidino-2-phenylindole (DAPI) containing mounting medium (Vector Laboratories). 
Slides were viewed using an inverted IX81 microscope (Olympus) equipped with a Retiga EXi 
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cooled CCD camera (Qimaging, Surrey, BC, Canada) and a MetaMorph software (Molecular 
Devices, San Jose, CA, USA). 
3.2.7 Inhibition of BMP-7 in vivo 
The calf muscle of the right leg of C57 BL/6J mice was injected with CTX as described above. 
One day later, the calf muscles of both legs were injected with 0.5 g BMP-2 (R&D Systems) 
either with 5 g BMP-7 neutralizing antibody (ab27569, abcam) or 5 g isotype control antibody 
(ab171870, abcam) coencapsulated in 50 L photocrosslinked methacrylated 8% (w/v) gelatin 
hydrogel scaffold. Two weeks later, mice were euthanized for imaging by microCT to detect the 
change in HO volume. Same scan setting was employed as previously described.  
3.2.8 Statistical analysis 
All data were expressed as mean ± SD. Student’s t-test was used to make comparisons between 
two groups, while one way ANOVA followed by the Tukey's multiple comparisons test was used 
for comparisons of three or more groups. Statistical significance (*) was considered at p < 0.05. 
Statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad Software 
Inc., LaJolla, CA, USA). 
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3.3 RESULTS 
3.3.1 CTX-induced muscle injury significantly increased HO volume 
To determine the role of muscle injury in HO formation, CTX was injected into the calf muscle 
of the right leg of the animal one day before BMP-2 injection into the calf muscles of both legs. 
Two weeks later, microCT imaging and analysis showed significantly larger bone volume in the 
right legs that were co-injected with CTX and BMP-2 (3.458±0.994 mm3), compared with the 
left legs that were injected with BMP-2 alone (1.573±0.577 mm3) (Figure 9A). Histology 
revealed severe inflammatory cell infiltration into the muscle tissue of the CTX-injured leg, 
while such infiltration was absent in the group with BMP-2 injection alone (Figure 9B). Bone 
tissue became evident after two weeks when most of the hydrogel vehicle had been degraded. 
There were no morphological differences (Supplemental Figure 1) between the bone formed in 
the different groups and no qualitative differences in bone mineral density (Figure 9A). 
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Figure 9. CTX-induced muscle injury significantly increased HO 
 (A) microCT imaging and analysis. Significantly larger HO volume was observed in the BMP-2/CTX co-injection 
group (right leg), compared to the group receiving BMP-2 injection alone (left leg) (*, p < 0.05; n = 4). No 
significant difference in bone mineral density was found between the two groups. (B) H&E staining illustrating the 
time course of HO progression. Severe inflammatory response in muscle tissue was seen at the early time points in 
the CTX-injured groups. Scale bar = 200 m.  
3.3.2 CTX-induced muscle injury generated an osteoinductive environment with BMP 
signaling activation 
CTX administration alone was not sufficient for the induction of HO and the inflammatory 
response was resolved after two weeks (data not shown). However, during this regeneration 
process, BMP signaling was activated with significantly higher phosphorylated Smad1 level 
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observed 7 days following muscle injury (Figure 10A). Osteogenic marker genes were also 
found to be upregulated with the expression of different genes peaking at different time points 
(Figure 10B), suggesting the generation of a pro-osteogenesis environment with highly 
coordinated gene regulation following muscle injury. 
To explore how this pro-osteogenesis environment could promote HO formation, muscle 
tissue derived conditioned medium was collected and applied to MDSCs in culture. After 
exposure to either GM or CM for two days, MDSC cultures were extracted for total protein at 
various time points after the change of medium on day 3. BMP signaling activation was observed 
immediately after the application of GM and CM (Figure 10C). However, the phosphorylation of 
Smad1/5 protein level diminished in GM group quickly but persisted in CM groups for an 
extended period of time. Phosphorylation of Smad1/5 protein level in CM groups peaked at the 
1-hour time point and remained the highest in the CTX CM treatment group thereafter (Figure 
10C). Exposure to CTX CM was also found to greatly enhance osteogenic marker gene 
expression in MDSCs, compared to exposure to CTL CM (Figure 10D). Concomitantly, 
BMPRIB gene expression increased significantly in MDSCs cultured in CTX CM (Figure 10D). 
Taken together, these results suggested that soluble factor(s) present in injured muscle tissue 
were able to promote MDSC osteogenesis via BMP signaling pathway. 
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Figure 10. CTX-induced muscle injury generated an osteoinductive environment 
(A) Phosphorylated Smad1 level in muscle tissue lysates measured by pSMAD1 ELISA at different time points 
following CTX injection demonstrated the activation of BMP signaling (**, p < 0.01; n = 3). (B) PCR analysis 
showed the upregulation of osteogenic marker gene expression in muscle tissue following CTX injection with the 
expression of different genes peaking at different time points. (*, p < 0.05; **, p < 0.01; ****, p < 0.0001; n = 3). 
Data are normalized to uninjected Day 0 control mice. (C) Western blot analysis of phosphorylated Smad1/5 protein 
and total Smad1 levels revealed the time course of BMP signaling activation in MDSCs cultured in GM and muscle 
tissue derived CM. (D) PCR analysis of osteogenic marker gene and BMP type I receptor gene expression in 
MDSCs. Significantly higher OSX, ALP, and BMPR1B expression was detected in MDSCs cultured in CTX CM 
compared to CTL CM (*, p < 0.05; n = 3). Data are normalized to MDSCs cultured in GM. 
3.3.3 BMP-7 level increased in CTX-injured muscle 
To identify the soluble factor(s) involved in BMP signaling activation, Western blotting was 
performed to examine the expression profile of several BMP ligands that have been reported to 
exhibit significant osteoinductive potential [116]. Among these BMP subtypes, we found that 
BMP-7 expression changed drastically with substantially increased expression 3 days following 
muscle injury, whereas BMP-2, BMP-4, BMP-9 expression remained relatively constant during 
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the muscle regeneration period (Figure 11A). Histology confirmed the expression of BMP-7 on 
CTX-injured muscle tissue at 48 hours after CTX injury, but not on control uninjured muscle 
tissue (Figure 11B). Histology also revealed severe inflammatory cell infiltration into the muscle 
tissue, suggesting the possibility that BMP-7 could be derived from the infiltrating inflammatory 
cells. Double immunofluorescence staining indeed demonstrated the presence of the macrophage 
marker, CD68, localized in close proximity to BMP-7 signals (Figure 11C). There were double 
positive cells as well as single positive cells for either marker in CTX-injured muscle tissue. 
 
Figure 11. BMP-7 level increased in CTX-injured muscle 
(A) Western blot analysis of the expression profile of selected BMP ligands following muscle injury. (B) H&E and 
IHC images showing the presence and distribution of BMP-7 in CTX-injured muscle tissue at 48 hours after CTX 
injury. Bar = 200 m. (C) Immunofluorescence staining showing the location of BMP-7 (green) in relation to 
macrophage marker CD68 (red) in CTX-injured muscle tissue. Arrowheads indicate the double positive cells present 
in CTX-injured muscle tissue. Bar = 20 m. 
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3.3.4 Inhibiting BMP-7 activity in vitro suppressed the osteogenesis-promoting effect of  
conditioned medium derived from CTX-injured muscle tissue 
To assess the functional involvement of BMP-7, the effect of supplementing BMP-7 neutralizing 
antibody to muscle tissue CM was tested on the promotion of MDSC osteogenesis, based on 
ALP activity and phosphorylated Smad1 level. Our results showed that ALP activity increased 
significantly in MDSCs cultured in CTX CM compared to CTL CM, and that this osteogenesis-
promoting effect of CTX CM was significantly inhibited in the presence of BMP-7 neutralizing 
antibody (Figure 12A). Concomitantly, addition of BMP-7 neutralizing antibody to CM resulted 
in the reduction of phosphorylated Smad1 to a nearly basal level (Figure 12B), validating the 
functional involvement of BMP-7 in BMP signaling activation in vitro. 
3.3.5 Inhibiting BMP-7 activity in vivo reduced HO volume 
To assess the in vivo relevance of the in vitro findings, BMP-7 neutralizing antibody was 
coencapsulated in hydrogel scaffold at the time of BMP-2 injection in the mouse HO model. 
microCT imaging and analysis at two weeks showed significantly reduced bone volume in both 
legs of animals receiving BMP-7 neutralizing antibody treatment (left leg: 0.3715±0.1016 mm3; 
right leg: 1.642± 0.5055 mm3), compared to animals receiving isotype control antibody 
treatment (left leg: 1.557±0.4149 mm3; right leg: 3.875±0.6129 mm3) (Figure 12C). No 
qualitative differences in bone mineral density were found between BMP-7 neutralizing antibody 
and isotype control antibody treatment groups (Figure 12C). 
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Figure 12. Inhibition of BMP-7 activity suppressed osteogenesis in vitro and reduced HO formation in vivo 
 (A) Osteogenesis of MDSCs in vitro. ALP activity measured in different groups of cell lysates showed that 
treatment with BMP-7 neutralizing antibody suppressed the osteogenesis-promoting effect of CTX CM (*, p < 0.05; 
**, p < 0.01; ****, p < 0.0001; n = 3). Iso: isotype control antibody treatment group; Ab: BMP-7 neutralizing 
antibody treatment group. (B) BMP signaling in vitro. Phosphorylated Smad1 level in cell lysates measured by 
pSMAD1 ELISA showed that activation of BMP signaling was inhibited with addition of BMP-7 neutralizing 
antibody (****, p < 0.0001; n = 3). (C) HO formation in vivo. microCT imaging and analysis showed significant 
reduction in HO volume upon BMP-7 neutralizing antibody treatment, compared with isotype control antibody 
treatment (*, p < 0.05; n = 4). No significant difference in bone mineral density was found between BMP-7 
neutralizing antibody and isotype control antibody treatment groups. 
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3.3.6 Suppression of inflammation reduced HO volume with concomitant reduction of 
BMP-7 production in CTX-injured muscle  
To assess the involvement of inflammation in HO formation, the anti-inflammatory drug, 
dexamethasone, was administered to the animals for 7 days to suppress the inflammatory 
response induced by muscle injury. microCT imaging and analysis at two weeks showed 
significantly reduced bone volume in both legs (left leg: 0.0803±0.119 mm3; right leg: 0.717±
0.396 mm3) (Figure 13A), compared to animals that did not receive anti-inflammatory drug 
treatment (left leg: 1.573±0.577 mm3; right leg: 3.458±0.994 mm3) (Figure 9A). Histological 
observation showed that, with dexamethasone administration, severe inflammatory cell 
infiltration into damaged muscle tissue was no longer evident in CTX-injured legs at the early 
time points (Figure 13B). In addition, the HO formed was less mineralized in both legs after 
dexamethasone treatment (left leg: 219.2±44.94 mg HA/ccm; right leg: 296.8±8.453 mg 
HA/ccm) (Figure 13A), compared to animals that did not receive anti-inflammatory drug 
treatment (left leg: 348.1±10.45 mg HA/ccm; right leg: 370±8.133 mg HA/ccm) (Figure 9A). 
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Figure 13. Suppression of inflammation reduced HO volume in vivo 
(A) microCT imaging and analysis. Reduction of HO volume and bone mineral density was observed in animals 
treated with the anti-inflammatory drug, dexamethasone (DEX) (*, p < 0.05; n = 4). (B) H&E staining illustrating a 
time course of HO progression in animals treated with anti-inflammatory drug. A diminished inflammatory response 
was found in CTX-injured muscle. Bar = 200 m. 
 
Immunofluorescence staining showed decreased CD68 positive macrophage numbers in 
CTX-injured muscle of dexamethasone-treated animals, compared to animals without 
dexamethasone treatment, at both the day 3 and day 7 time points (Figure 14). Importantly, in 
addition to decreased macrophage number in dexamethasone-treated group, BMP-7 level in 
CTX-injured muscle tissue was also greatly reduced at the day 3 time point (Figure 14A&B). 
BMP-7 expression was only detectable within 3 days following CTX injury, and was 
undetectable beyond the acute inflammatory phase (Figure 14A&C). 
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Figure 14. Suppression of inflammation in vivo reduced BMP-7 level in CTX-injured muscle 
(A) Immunofluorescence staining showing decreased macrophage number (CD68, red) and reduced BMP-7 level 
(green) in CTX-injured muscle in animals treated with the anti-inflammatory drug, dexamethasone (DEX). Bar = 
200 m. (B&C) Quantitative analysis of BMP-7+ and CD68+ cells at the interface of hydrogel scaffold and muscle. 
Cell counts of BMP-7+ and CD68+ cells were done on 6 independent fields of view (FOV, 20× magnification). (B) 
On day 3, significant decrease in the number of BMP-7+ and CD68+ cells was observed in dexamethasone-treated 
animals (*, p < 0.05; **, p < 0.01). (C) On day 7, significant decrease in the number of CD68+ cells was observed in 
dexamethasone-treated animals (**, p < 0.01), while BMP-7+ cells were not detected. 
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3.4 DISCUSSION AND CONCLUSION 
In this study, we first set out to determine the role of muscle injury in HO formation by using 
CTX to induce muscle injury in a BMP-2-induced HO mouse model. Our results showed that 
CTX-induced muscle injury significantly increased the volume of BMP-2-induced HO (Figure 
9A) together with increased osteogenic marker gene expression (Figure 10B) and increased level 
of phosphorylated Smad1 (Figure 10A), suggesting the generation of a pro-osteogenesis 
environment after CTX treatment. 
Next, we sought to explore by which mechanism muscle injury facilitates HO formation. 
To test the possibility that soluble factors present in damaged muscle tissue have an 
osteogenesis-promoting effect, we compared the effect of exposing MDSCs to culture medium 
conditioned by explanted control muscle tissue (CTL CM) versus that conditioned by explanted 
CTX-injured muscle tissue (CTX CM). MDSC is likely the same cell type identified as the 
muscle interstitial resident FAPs previously found to mediate BMP-2-induced HO in vivo [19, 
24]. The MDSCs used in this study are positive for the surface markers Sca-1 and PDGFR, 
have strong osteogenic potential, and are highly responsive to BMP signal in vitro (Supplemental 
Figure 2). Our data showed that CTX CM is capable of promoting osteogenesis by upregulating 
osteogenic marker gene and BMP receptor gene expression in MDSCs (Figure 10D) along with 
BMP signaling activation (Figure 10C), suggesting that certain BMP family proteins are present 
in the damaged muscle milieu and are capable of exerting an osteogenesis-promoting effect on 
MDSCs. Notably, we also found that CTL CM is also capable of promoting MDSCs 
osteogenesis and activates BMP signaling compared with GM, but to a lesser extent than CTX 
CM. We speculate that this is either because certain pro-osteogenesis factors are present at basal 
level in uninjured muscle tissue or muscle tissue was unavoidably injured during its collection 
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process resulting from incision and cutting.  In summary, our findings suggest a general 
mechanism by which muscle injury facilitates HO formation via the soluble factors present in 
injured muscle that induce MDSC osteogenesis through BMP signaling pathway.  
To identify which soluble factor is responsible for BMP signaling activation following 
muscle injury, Western blotting was performed against selected BMP subtypes that have been 
reported with great osteoinductive potential. We found that BMP-7 expression was highly 
upregulated at early time points following muscle injury, and that its expression was localized 
only to inflamed areas of muscle tissue highly populated by CD68 positive macrophages (Figure 
11). We did not observe the change in expression of other BMP subtypes in injured muscle 
tissue. As ligand specificity of BMP signaling is mainly dictated by BMP type I receptor, with 
BMP-2/4 having a higher affinity for BMPRIA and BMP-6/7 for BMPRIB [117], the 
upregulation of BMP-7 was consistent with our in vitro finding that among the BMP type I 
receptors only BMPRIB expression was significantly upregulated in MDSCs after being exposed 
to muscle tissue CM (Figure 10D). To confirm the functional involvement of BMP-7, we 
performed BMP-7 inhibition experiment both in vitro and in vivo. Treatment with BMP-7 
neutralizing antibody significantly inhibited the osteogenesis-promoting effect of CTX CM in 
vitro and reduced HO volume in vivo (Figure 12), strongly implicating the role of BMP-7 as a 
key osteoinductive factor responsible for the osteogenesis-promoting effect of muscle injury. 
BMP-7, also known as osteogenic protein-1, is an FDA-approved osteoinductive adjuvant 
in orthopedic surgery known for its role in triggering stem cell osteogenic differentiation [118]. 
However, the physiological role of BMP-7 following muscle injury and its cellular origin is not 
clear at this point. Previous studies have shown that BMP signaling is normally active in muscle 
and important in maintaining muscle mass, and that inhibition of BMP signaling leads to muscle 
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antrophy [9, 119]. Studies have also shown that BMP signaling is indispensable for muscle 
regeneration following injury, and BMP signaling activation coincides with the period of satellite 
cell proliferation [10]. Therefore, BMP-7 may function to promote satellite cell proliferation in 
injured muscle [120, 121]. Recently, it has become clear that BMP-7 is a highly pleiotropic 
factor [122]. For example, it has been reported that BMP-7 inhibits inflammation by inducing 
M2 macrophage differentiation [123]. It can also act as an anti-fibrotic cytokine by antagonizing 
TGF-β1 [124-126]. Given the close spatial proximity of BMP-7 signal and macrophage signal 
observed by immunofluorescence staining, the upregulation of BMP-7 in injured muscle may 
also be a mechanism to counteract muscle injury-induced inflammation and fibrosis. However, in 
pathological conditions, such as in our case with supraphysiological doses of BMP-2, this 
physiological BMP-7 signal may well turn into strong osteogenic signal to cause aberrant 
osteogenesis. 
Lastly, we showed that anti-inflammatory drug treatment reduced the volume of HO 
formation in vivo, with evident decreases in inflammatory cell infiltration (Figure 13). In 
addition, we found decreased BMP-7 level in CTX-injured muscle tissue in dexamethasone-
treated animals compared with those not receiving the drug (Figure 14). The positive correlation 
between BMP-7 levels and macrophage numbers suggests that the osteogenesis-promoting effect 
of muscle injury could be largely related to the injury-induced inflammatory response. Our 
results thus provide a possible rationale for using anti-inflammatory drugs as HO prevention. 
Interestingly, we also observed in our study that either inhibition of BMP-7 activity or 
suppression of inflammation reduced the volume of HO in the left legs subjected only to BMP-2 
injection. This can be explained by the fact that recombinant BMP triggers dose-dependent 
inflammatory reactions in vivo [127], and hydrogel muscle injection may cause mild muscle 
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tissue injury. Indeed, we observed BMP-7 expression located at the interface of BMP-2 hydrogel 
and muscle in the BMP-2 injection alone group, which became even less evident in animals 
receiving anti-inflammatory drug treatment (data not shown). 
In summary, our results demonstrate that locally produced BMP-7 following muscle 
injury could be a key factor in facilitating HO formation, and the osteogenesis-promoting effect 
is largely related to the muscle injury-induced inflammatory response. We also tested this 
postulation in our mouse blast-amputation model, and showed that BMP-7 level was highly 
upregulated 3 days following blast injury (Figure 15), suggesting that BMP-7 might play a 
universal role in different types of muscle injury. Our lab's previous study has demonstrated the 
presence of BMP-4 ligand in human blast traumatized skeletal muscle tissue [128]. However, we 
did not find upregulation of BMP-4 in our mouse blasted muscle tissue. This may be due to 
different injury mechanism, tissue harvest time, and differences between human and mouse. 
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Figure 15. BMP-7 expression in mouse blast-traumatized muscle 
(A-C) H&E staining illustrating muscle tissue morphology at different time points following blast injury: (A) 
uninjured muscle tissue; (B) 3 day post injury; (C) 7 day post injury. Scale bar = 200 m (D-F) 
Immunofluorescence staining showing the expression of BMP-7 at different time points following blast injury: (D) 
uninjured muscle tissue; (E) 3 day post injury; (F) 7 day post injury. Scale bar = 200 m (G-I) Immunofluorescence 
staining using isotype control antibody: (G) uninjured muscle tissue; (H) 3 day post injury; (I) 7 day post injury. 
Scale bar = 200 m 
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4.0  ROLE OF CORTISOL STRESS RESPONSE IN HO PATHOGENESIS 
Chapter 4 is adapted from a research article submitted to Journal of Bone and Mineral Research 
Li L., Xiang S., Wang B., Lin H., Kihara S., Sun H., Alexander P.G., Tuan R.S.. TGF-β1 plays a 
protective role in glucocorticoid-induced dystrophic calcification. (submitted November 2019) 
4.1 INTRODUCTION 
As mentioned above, the pathogenesis of acquired HO is not well understood. However, it is 
noteworthy that acquired HO happens most frequently in severe trauma patients such as 
following blast injury, central nerve system injury, and burn injury, when the body is under great 
stress, a condition under which excessive endogenous glucocorticoid production has always been 
found [129]. Glucocorticoids are one type of stress hormones, which exert strong 
immunosuppressive effects to confine body immune responses being overactivated in life-
threatening situations [130]. Endogenous cortisol production can rise to 240 mg per day under 
stress, whereas the normal daily production is about 10 mg per day [131], and the secretion level 
of glucocorticoids can reflect the severity of injury [132, 133]. Glucocorticoids have a big impact 
on bone and muscle: glucocorticoid excess, both pathological elevation and long-term 
therapeutic use, could result in osteoporosis and muscle atrophy [134]. It has also been reported 
that cortisol stress response is associated with pathological calcification in the cardiovascular 
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system [135, 136]. However, few studies have investigated the impact of glucocorticoids on 
DC/HO formation in the musculoskeletal system. Based on reported clinical observations, we 
hypothesized that high glucocorticoid level could result in an increased incidence of DC/HO. In 
this study, we administered a high dose of a synthetic glucocorticoid, dexamethasone (DEX), to 
animals with muscle injury induced by cardiotoxin (CTX) injection to mimic a glucocorticoid 
excess state following severe muscle trauma, in order to determine the role of glucocorticoids in 
DC/HO pathogenesis and the possible underlying mechanism. 
It has recently been demonstrated that decreased plasmin level is associated with DC/HO 
formation [112, 137]. In these studies, the authors claimed that perturbation in the fibrinolytic 
system could be the underlying mechanism for traumatic HO, since hypofibrinolysis is a 
common occurrence upon traumatic injury. Interestingly, glucocorticoids also play a role in the 
fibrinolytic system, namely it increases plasminogen activator inhibitor-1 (PAI-1) level, which in 
turn decreases plasmin level, therefore leading to a state of hypercoagulation [138]. Increased 
PAI-1 level has been reported to be associated with pathological calcification in the 
cardiovascular system [139, 140]. In the musculoskeletal system, PAI-1 expression is negatively 
correlated with muscle regeneration [141, 142]. Since DC/HO could be regarded as a result of 
impaired tissue regeneration [143], we hypothesized that glucocorticoid excess could impair 
muscle regeneration and promote DC/HO through alterations in PAI-1 and plasmin levels. 
The plasmin substrate that is responsible for DC/HO formation is unknown. A well-
known plasmin target is transforming growth factor-beta 1 (TGF-β1), an inducer of PAI-1 and 
also a key factor involved in muscle regeneration and pathological calcification [99, 144]. 
However, there is no existing, conclusive evidence regarding the role of TGF-β1 in DC/HO 
formation. TGF- appears to inhibit stem cell osteogenesis [145-148], whereas when its effects 
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on the immune and other systems are taken into consideration, its role can be pro-osteogenic [99, 
149-152]. In this study, we have sought to evaluate the functional involvement of TGF-β1 in 
glucocorticoid-induced DC, and the results reported here show a protective role of TGF-β1 in 
glucocorticoid-induced DC. 
4.2 METHODS 
4.2.1 In vivo induction of DC/HO 
Using a protocol approved by the Institutional Animal Care and Use Committee (Protocol No. 
18032493), the calf muscle of 8-week-old male C57BL/6J mice (Jackson Laboratory, Bar Harbor, 
ME, USA) were injected once with 50 L of 10 M CTX (Calbiochem, San Diego, CA, USA) to 
induce muscle injury [153]. Mice were also subcutaneously injected with 10 mg/kg DEX (Henry 
Schein, Dublin, OH, USA) daily until the day of sacrifice. CTX injection alone or DEX injection 
alone served as control. Mice were then euthanized at different time points for imaging by 
microCT (Scanco Medical vivaCT 40, Brüttisellen, Switzerland) to detect ectopic mineralization. 
Scans were acquired at 45 kVp, 88 A, 300 ms integration time and at an isotropic voxel size of 
35 m. Bone volume was calculated by selecting region of interest that was drawn to include the 
opaque area of DC/HO at each 2D slices but to exclude the tibia and fibula area. Bone mineral 
density was calculated as mg hydroxyapatite (HA)/volume (cubic centimeter, ccm). 
For administration of corticosterone (R&D Systems, Minneapolis, MN, USA), 
corticosterone was dissolved in DMSO and subcutaneously injected daily, with corn oil vehicle 
containing 5% DMSO. Mice were also injected with CTX. Mice were euthanized at Day 7 time 
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point for imaging by microCT. Mice injected daily with corn oil vehicle containing 5% DMSO 
combined with CTX treatment served as control. 
4.2.2 Histology 
Following microCT analysis, muscle tissues were isolated and fixed in methanol and paraffin 
embedded. For histology, sections (9 m thick) were collected on ColorFrost Plus microscope 
slides (ThermoFisher Scientific, Waltham, MA, USA) and dried overnight. Hematoxylin and 
Eosin (H&E), Alizarin Red, and Safranin-O staining were performed according to routine 
protocols. Images were taken using a CKX41 microscope (Olympus, Tokyo, Japan) equipped 
with a DFC 3200 camera (Leica, Wetzlar, Germany). 
For immunofluorescence staining, tissue sections were decalcified in 0.5 M 
ethylenediaminetetraacetic acid (EDTA) for 1 hour and blocked in 10% bovine serum albumin 
for 10 min. Sections were incubated in primary antibodies against platelet-derived growth factor 
receptor α (PDGFRα) (AF1062, R&D Systems, Minneapolis, MN, USA) and bone 
morphogenetic protein-7 (BMP-7) (ab56023; abcam, Cambridge, MA, USA) overnight at 4 °C. 
On the second day, sections were incubated with secondary antibodies against goat IgG 
(ab150130; abcam) and rabbit IgG (ab150077; abcam) at room temperature for 1 h. After 
washing, the slides were mounted with 4′,6-diamidino-2-phenylindole (DAPI)-containing 
mounting medium (Vector Laboratories Inc., Burlingame, CA, USA). Slides were viewed using 
an inverted IX81 microscope (Olympus) equipped with a Retiga EXi cooled CCD camera 
(Qimaging, Surrey, BC, Canada) and MetaMorph software (Molecular Devices, San Jose, CA, 
USA). 
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4.2.3 Blood sample and muscle tissue collection  
Blood sample was collected by cardiac puncture at the time of animal sacrifice. Mice were 
sacrificed at Day 3, 7, and 14 time points in (1) CTX+DEX co-treatment group; (2) CTX 
treatment alone group; and (3) DEX treatment alone group. In each group, untreated mice served 
as Day 0 control, and all data in one group were normalized to its Day 0 control. Blood was 
collected into an EDTA anticoagulant tube and centrifuged. Supernatant was collected for 
plasma protein analysis using commercial enzyme-linked immunosorbent assay (ELISA) kits 
purchased from abcam. 
Following blood sample collection, muscle tissue samples were also collected at Day 3, 
7, and 14 time points in the above-mentioned groups, with untreated mice serving as Day 0 
control. Briefly, calf muscles from left and right sides were isolated and immediately snap-frozen 
in liquid nitrogen for later tissue RNA and protein extraction. Muscle tissue gene expression was 
determined by quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) 
analysis and protein analysis by ELISA. 
4.2.4 qRT-PCR analysis  
Muscle tissues or cells were lysed in QIAzol Lysis Reagent and isolated using the RNeasy Mini 
Kit according to the manufacturer’s instructions (QIAGEN, Hilden, Germany). RNA was then 
converted to cDNA using the SuperScript™ IV First-Strand Synthesis System (Invitrogen, 
Carlsbad, CA, USA). Quantitative real-time PCR was performed with a StepOne Plus Realtime 
PCR system using PowerUp™ SYBR® Green Master Mix (Applied Biosystems, Foster City, 
CA, USA). The relative level of gene expression was calculated using the 2-delta delta Ct 
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method. Primer sequences for actin, runt-related transcription factor 2 (Runx2), bone sialoprotein 
I (Bsp1), osterix (Osx), PAI-1 (Pai1), TGF-β1 (Tgfb1), alkaline phosphatase (Alp), osteocalcin 
(Ocn) are listed in Table 1. 
4.2.5 In vivo supplementation of TGF-β1 
CTX and DEX treatments were the same as described above. For in vivo supplementation of 
TGF-β1, mice were subcutaneously injected with 100 g/kg mouse TGF-β1 recombinant protein 
(ThermoFisher Scientific) daily for 7 days. Mice injected with saline served as control. At Day 7 
and Day 14, mice were euthanized for microCT analysis of ectopic mineralization. Identical scan 
setting as described above was employed. Blood samples and muscle tissue samples were also 
collected for protein and gene expression analysis. 
4.2.6 In vitro osteogenesis induction in muscle-derived stromal cells 
To determine the effect of TGF-1 on osteogenic differentiation of muscle-derived stromal cells 
(MDSCs) in vitro, MDSCs were harvested from another cohort of mice according to a previously 
described protocol [115]. MDSCs at passage 3 were used to perform the experiment. Briefly, 0.2 
million cells were seeded into each well in a 6-well plate, and were maintained in high-glucose 
Dulbecco's Modiﬁed Eagle's Medium (GIBCO, Gaithersburg, MD, USA) supplemented with 
20% fetal bovine serum (Gemini Bio Products, West Sacramento, CA, USA) and 1% 
penicillin/streptomycin (GIBCO). On the following day, cells were treated with either 50 ng/ml 
BMP-7 (R&D Systems) or 50 ng/ml BMP-7 plus 20 ng/ml TGF-1 (R&D Systems) for three 
days. On culture Day 4, MDSCs were collected for PCR analysis of osteogenic marker gene 
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expression. MDSCs cultured in growth medium without BMP-7 and TGF-1 treatment served as 
control. 
4.2.7 Statistical analysis 
All data were expressed as mean ± SD. N ≥ 4 for each group of in vivo animal experiments. 
Student’s t-test was used to make comparisons between two groups, and one-way or two-way 
ANOVA followed by the Tukey's multiple comparisons test was used for comparisons of three 
or more groups. Statistical significance (*) was considered at p < 0.05. Statistical analyses were 
performed using GraphPad Prism 7.0 software (GraphPad Software Inc., LaJolla, CA, USA). 
4.3 RESULTS 
4.3.1 Glucocorticoid treatment stimulated ectopic mineralization 
To determine the role of glucocorticoids in DC/HO pathogenesis, DEX was administered 
following muscle injury induced by CTX. microCT imaging and analysis showed that combined 
CTX and DEX treatment caused a significant amount of mineralization in the calf muscles of the 
animal, while either of the treatment alone could not result in ectopic mineralization (Figure 
16A-C). Ectopic mineralization was found evident at Day 7 time point post muscle injury, and 
there was no significant change in bone volume until Day 21 (Figure 16D). However, there was a 
significant increase in bone mineral density, suggesting an active remodeling process progressing 
over the intervening time period (Figure 16D). We initially used a lower 1 mg/kg DEX dose and 
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found that ectopic mineralization could only be observed in about 40% of the treated animals, 
whereas 10 mg/kg DEX treatment stimulated ectopic mineralization in ~90% of the animals. 
Among all the animals with ectopic mineralization, an obvious trend of larger bone volume was 
found in higher DEX dose group compared with lower DEX dose group, and the lower DEX 
dose group appeared to show a more rapid clearance of mineralization, as decreased bone 
volume and bone mineral density was found at Day 21 time point in the 1 mg/kg DEX dose 
group (Figure 16D). Mice were monitored daily for reactivity and body weight. There were no 
signs of discomfort in mice with DEX treatment at our current doses and body weight was not 
affected by the treatment (Supplemental Figure 3). 
We also tested another more physiological relevant glucocorticoid, corticosterone, which 
is the major glucocorticoid in rodents [154]. We demonstrated that combined CTX and 
corticosterone treatment elicited the same effect as combined CTX and DEX treatment 
(Supplemental Figure 4). There was no significant difference between the lower 20 mg/kg and 
the higher 40 mg/kg corticosterone dose treatment groups at Day 7 in terms of bone volume and 
density (Supplemental Figure 4). Treatment with corticosterone seemed to achieve a higher 
positive rate compared with DEX treatment. However, since there is no commercial available 
corticosterone solution for injection and given the low solubility of corticosterone, a considerable 
amount of corn oil vehicle needed to be used, which could accumulate subcutaneously with 
repeated daily injection, thus compromising the long-term administration of corticosterone. 
Therefore, we chose to use DEX injection for the following study. We also demonstrated that 
repeated daily subcutaneously injection was not likely to cause sufficient stress in itself to induce 
ectopic mineralization, given that daily vehicle injection combined with CTX treatment did not 
result in ectopic mineralization (Supplemental Figure 4). 
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Figure 16. Glucocorticoid treatment stimulated ectopic mineralization 
 (A) microCT imaging illustrating the time course of ectopic mineralization formed in CTX+DEX co-treatment 
group. Arrowheads indicate ectopic mineralization. (B) microCT imaging demonstrating that CTX treatment alone 
did not result in ectopic mineralization. (C) microCT imaging demonstrating that DEX treatment alone did not result 
in ectopic mineralization.  (D) microCT analysis of bone volume and bone mineral density in 10 mg/kg and 1 mg/kg 
CTX+DEX co-treatment groups. (*, p < 0.05; **, p < 0.01; ***, p < 0.001; n = 4) 
4.3.2 Glucocorticoid treatment caused impaired muscle regeneration and enhanced 
osteogenesis 
Histology revealed severe inflammatory cell infiltration into the CTX-injured muscle tissue at 
the Day 3 time point. In the CTX administration alone group, inflammatory response was 
efficiently resolved in two weeks as regenerated muscle fibers with centrally located nuclei were 
found as early as Day 7 (Figure 17A). However, such process was not found in the CTX+DEX 
co-treatment group. Instead, massive calcification deposits were found in the degenerating 
muscle fibers and inflammatory cells were still present at the Day 14 time point (Figure 17A&B). 
Increased expression of osteogenic marker genes, including Runx2, Bsp1, and Osx, was also 
observed in CTX+DEX co-treatment group, suggesting enhanced osteogenesis accompanying 
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impaired muscle regeneration (Figure 17C). In rare cases, DC can progress into HO within 2 
weeks through an endochondral ossification process as demonstrated by positive Safranin-O 
staining (Supplemental Figure 5). In comparison, DEX treatment alone did not appear to affect 
muscle morphology nor the expression of osteogenic marker genes during the 14-day time 
course (Figure 17A-C).  
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Figure 17. Glucocorticoid treatment caused impaired muscle regeneration and enhanced osteogenesis 
 (A) H&E staining showing the muscle regeneration processes, in which impaired muscle regeneration was observed 
in CTX+DEX co-treatment group. Bar = 50 m. (B) Alizarin Red staining showing massive calcium depositions 
found in CTX+DEX co-treatment group. Bar = 50 m. (C) PCR analysis of osteogenic marker gene expression in 
muscle tissue. Significant upregulation of expression of osteogenic marker genes (Runx2, Bsp1, Osx) was found in 
CTX+DEX co-treatment group over the 14-day time course. Gene expression levels are normalized to that of Actin. 
(*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; n = 4). 
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Increased PAI-1 level, an indicator of impaired muscle regeneration, was observed in 
CTX+DEX co-treatment group compared with CTX treatment alone group, both systemically 
(plasma) and locally (muscle tissue lysates) (Figure 18A&B). In addition, muscle production of 
PAI-1 was increased in CTX+DEX co-treatment group compared with CTX treatment alone 
group (Figure 18C). DEX treatment alone did not affect plasma or muscle tissue PAI-1 level 
(Figure 18A-C). 
 
Figure 18. Glucocorticoid treatment caused increased PAI-1 level in CTX-injured muscle 
(A) Blood sample analysis of PAI-1 level. CTX+DEX co-treatment increased plasma PAI-1 level. (*, p < 0.05; n = 4) 
(B) Muscle tissue sample analysis of PAI-1 level. CTX+DEX co-treatment increased muscle PAI-1 level. (****, p < 
0.0001; n = 4). (C) PCR analysis of Pai1 expression in muscle tissue. CTX+DEX co-treatment increased muscle 
Pai1 expression. (***, p < 0.001; ****, p < 0.0001; n = 4). In each analysis, PAI-1 levels are normalized to Day 0 
untreated control. 
4.3.3 Lowered circulating TGF-1 level correlated with DC formation  
The above findings prompted us to next examine the circulating level of plasmin, the 
downstream target of PAI-1. ELISA results showed that plasmin level decreased over time in the 
CTX+DEX co-treatment group, while remaining relatively constant in the CTX treatment alone 
or the DEX treatment alone groups (Figure 19A). Accompanying the decreased plasmin level, 
muscle fibrin level was found to be significantly increased in the CTX+DEX co-treatment group 
(Figure 19B). At Day 3, a slight decrease in fibrin level was observed in the DEX treatment 
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alone group, and a significant increase in fibrin level was observed in the CTX treatment alone 
group (Figure 19B). However, muscle fibrin level in these two groups returned to baseline after 7 
days (Figure 19B). 
To explore the functional relationship between lowered plasmin level and DC/HO 
formation, we checked the expression of TGF-1, a downstream target of plasmin. Our results 
showed that DEX treatment in the course of CTX-induced muscle injury resulted in a significant 
reduction in circulating TGF-1 level, as well as reduced Tgfb1 gene expression in muscle tissue 
as demonstrated by PCR analysis (Figure 19C&D). In comparison, CTX treatment alone did not 
affect plasma TGF-1 level nor muscle Tgfb1 gene expression, while DEX treatment alone 
decreased TGF-1 level as well as muscle Tgfb1 gene expression, although not in a statistically 
significant manner (Figure 19C&D). 
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Figure 19. Glucocorticoid treatment caused decreased circulating TGF-1 level 
 (A) Plasma levels of plasmin. CTX+DEX co-treatment caused a significant decrease in plasma plasmin level. (*, p 
< 0.05; ****, p < 0.0001; n = 4). (B) Fibrin levels in muscle tissue. CTX+DEX co-treatment caused a significant 
increase in muscle fibrin level. (*, p < 0.05; ****, p < 0.0001; n = 4). (C) TGF-1 levels in plasma. CTX+DEX co-
treatment caused a significant decrease in plasma TGF-1 level. (*, p < 0.05; **, p < 0.01; ***, p < 0.001; n = 4). (D) 
PCR analysis of Tgfb1 gene expression in muscle tissue. CTX+DEX co-treatment caused a significant decrease in 
muscle Tgfb1 expression. (**, p < 0.01; n = 4). 
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4.3.4 TGF-1 supplementation inhibited DC formation  
To assess the functional involvement of TGF-1 in DC/HO pathogenesis, recombinant mouse 
TGF-1 protein was systemically administered for 7 days in addition to CTX+DEX co-
treatments. Compared to saline treatment, TGF-1 treatment significantly reduced bone volume 
(Saline: 1.385±0.3251 mm3; TGF-1: 0.3377±0.1832 mm3) at Day 7 (Figure 20A&B). No 
qualitative differences in bone mineral density were found between saline treatment group and 
TGF-1 treatment group (Saline: 297.3± 5.699 mg HA/ccm; TGF-1: 285.1± 12.78 mg 
HA/ccm) at Day 7 (Figure 20A&B). Decreased osteogenic marker gene expression was also 
observed upon TGF-1 treatment, suggesting suppression of osteogenesis (Figure 20C). 
Interestingly, the effect of 7-day TGF-1 treatment persisted, as significantly reduced bone 
volume (Saline: 2.568±1.052 mm3; TGF-1: 0.2757±0.09123 mm3) as well as reduced bone 
mineral density (Saline: 330.6±9.395 mg HA/ccm; TGF-1: 297.3±8.944 mg HA/ccm) 
(Supplemental Figure 6) were seen at least until Day 14. 
Given the known upregulation of PAI-1 production by TGF-1, we examined the 
influence of TGF-1 supplementation on plasma and muscle PAI-1 level. TGF-1 
supplementation significantly increased plasma and muscle tissue PAI-1 levels (Figure 20D&E), 
possibly correlated with increased DC formation. However, eventually reduced bone volume was 
observed with TGF-1 supplementation (Figure 20A&B), suggesting that TGF-1 could be the 
effector of the fibrinolytic system to regulate DC formation (Figure 20F). 
 62 
 
Figure 20. TGF-1 supplementation inhibited DC formation 
 (A) microCT imaging demonstrating reduced bone volume with TGF-1 supplementation. Arrowheads indicate 
ectopic mineralization. (B) microCT analysis of bone volume and bone mineral density with and without TGF-1 
supplementation (*, p < 0.05; n = 6). (C) PCR analysis of osteogenic marker gene expression in muscle tissue with 
and without TGF-1 supplementation. Significant downregulation of osteogenic marker gene expression was found 
with TGF-1 supplementation. (**, p < 0.01; ***, p < 0.001; n = 3). (D) In vivo TGF-1 supplementation 
significantly increased plasma PAI-1 level. (***, p < 0.001; n = 3). (E) In vivo TGF-1 supplementation 
significantly increased muscle tissue PAI-1 level. (***, p < 0.001; n = 3). (F) Schematic of negative feedback loop 
between PAI-1 and TGF-1. 
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4.3.5 Possible mechanism of TGF-1 in regulating DC formation  
We have recently shown that muscle injury promotes HO by stimulating local BMP-7 production 
[155]. As TGF-1 could act to antagonize BMP-7 activity by competing for their downstream 
co-Smad4 signaling component for nuclear signal transduction, we hypothesized that the 
reduction in circulating TGF-1 level would attenuate the inhibitory effect of TGF-1 on BMP-
7, thereby promoting BMP-7-induced osteogenesis. Interestingly, we observed high cell density 
in the local tissue surrounding the calcium deposits, suggesting active tissue remodeling (Figure 
21A). In addition, a great number of cells positive for PDGFRα, a marker of mesenchymal stem 
cells, were observed near the calcium deposits, suggesting the participation of muscle resident 
stem cells in DC formation and remodeling (Figure 21B). Furthermore, we also detected strong 
BMP-7 immunostaining surrounding the calcium deposits, suggesting that the muscle resident 
stem cell population could be under the regulation of BMP-7 signal (Figure 21B). This possible 
mechanism was tested in vitro using cultured MDSCs treated with BMP-7 and TGF-1. Our 
results showed that in vitro supplementation of TGF-1, at a concentration similar to that in 
plasma, almost completely blocked BMP-7-induced osteogenesis, evidenced by the marked 
downregulation of osteogenic marker gene expression (Figure 21C), suggesting that TGF-1 
could negatively regulate osteogenesis, specifically that induced by BMP-7. 
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Figure 21. Cellular effects of TGF-1 supplementation on glucocorticoid mediated osteogenesis in vivo 
and in vitro 
(A) H&E staining of undecalcified and decalcified muscle tissue obtained 7 days following CTX+DEX co-treatment. 
High cell density was found surrounding the calcium deposits. Bar = 50 m. (B) Immunofluorescence staining 
showing the PDGFRα (red) positive cells and BMP-7 (green) positive cells surrounding the calcium deposits. Bar = 
50 m. (C) PCR analysis of osteogenic marker gene expression in MDSCs treated with BMP-7 alone or with BMP-
7 and TGF-1. In vitro TGF-1 supplementation almost completely blocked BMP-7-induced osteogenesis in 
MDSCs. (**, p < 0.01; ****, p < 0.0001; n = 3). 
4.4 DISCUSSION AND CONCLUSION 
In this study, we sought to determine the role of glucocorticoids in DC/HO formation following 
muscle injury. We have previously shown in a BMP-2-induced HO mouse model that BMP-7 
production by resident cells following muscle injury promotes HO [155]. However, muscle 
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injury alone, although generating a pro-osteogenesis environment, seldom led to HO formation 
[155]. This suggests that other factors are required for ectopic mineralization [108]. In our 
previous study, a strong osteoinductive signal, i.e., supraphysiological dose of BMP-2, was 
present for inducing bone formation. However, under most physiological conditions, such strong 
osteoinductive signals are usually not present. Recently, a novel notion has been proposed for the 
mechanism of ectopic mineralization, namely instead of the presence of a strong osteoinductive 
signal, protective factors may be removed under pathophysiological conditions, allowing calcium 
deposition to take place [112]. In this study, we set out to explore, in addition to muscle injury, 
what the other factors are that may affect DC/HO formation. 
We have chosen to focus on glucocorticoids as excessive endogenous glucocorticoid 
production has always been found following severe trauma, which coincides with increased HO 
incidence. In this study, we treated animals with high dose DEX following muscle injury, and 
our results showed that DEX treatment together with CTX-induced muscle injury resulted in a 
significant amount of DC in muscle (Figure 16A), while neither of the treatment alone could 
cause DC formation (Figure 16B&C). This DEX-induced response is dose-dependent response, 
evidenced by the higher positive rate and larger bone volume in the higher dose, 10 mg/kg DEX 
group compared to the lower dose 1 mg/kg DEX group (Figure 16D). In addition, the higher 
DEX dose presented sustained calcification, while in the lower DEX dose group, DC quickly 
diminishes over time (Figure 16D). Histologically, CTX+DEX co-treatment leads to impaired 
muscle regeneration (Figure 17A), which appears to lead to DC and enhanced osteogenesis 
(Figure 17B&C). PAI-1 level, as an indicator of impaired muscle regeneration, was found 
increased in CTX+DEX co-treatment group as well (Figure 18A-C). Taken together, these data 
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suggest that glucocorticoids stimulate DC formation, possibly by interfering with muscle 
regeneration. 
We next sought to explore the mechanism responsible for glucocorticoid-mediated 
promotion of DC/HO formation. The fibrinolytic system has recently been reported to be 
associated with DC/HO formation, in which plasmin protects against muscle injury-induced DC 
[112]. We observed that PAI-1, a key regulatory component in the fibrinolytic system, is 
significantly upregulated upon CTX+DEX co-treatment, i.e., the group with DC formation 
(Figure 18A-C). The action of PAI-1, a serine protease inhibitor which inhibits tissue 
plasminogen activator and urokinase plasminogen activator, results in decreased plasmin level 
and thus increased fibrin accumulation (Figure 20F). Interestingly, decreased circulating plasmin 
level and increased muscle fibrin accumulation are also found in the CTX+DEX co-treatment 
group (Figure 19A&B), suggesting that glucocorticoids may indeed play a role as an upstream 
regulator of the fibrinolytic system in facilitating DC/HO formation. The plasmin substrate that 
is responsible for DC/HO formation needs to be identified. Recent reports by Schoenecker’s 
group show that although delayed fibrin clearance has been associated with impeded 
macrophages invasion and subsequent enhanced osteogenesis, knocking down fibrinogen has 
failed to rescue low plasmin level-induced DC/HO formation [108, 112]. These authors suggest a 
number of plasmin substrates, including parathyroid hormone, fibroblast growth factor 23 and 
vitamin D, which are important hormones in regulating calcium and phosphate metabolism. 
However, given the definition of DC, which is calcium deposition under physiologically normal 
serum calcium and phosphate conditions, we are more inclined to believe that the plasmin 
substrate should be more of an injury-related factor. 
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TGF-β1 is a well-known target of plasmin, which releases active TGF-β1 from its 
latency-associated peptide [156]. TGF-β1 is also the strongest inducer of PAI-1 [157]. When 
active TGF-β1 level increases, elevated PAI-1 level prevents further increase in TGF-β1 level. 
This negative feedback mechanism maintains homeostasis of the fibrinolytic system, although it 
may exhibit certain level of hysteresis [158]. In this study, we demonstrated that increased PAI-1 
level in the CTX+DEX co-treatment group is associated with decreased plasmin and TGF-β1 
level (Figure 19A&C). Since TGF-β1 is also a key factor involved in muscle regeneration and 
pathological calcification, we hypothesize that TGF-β1 could be the downstream effector of the 
fibrinolytic system to regulate DC formation. We tested our hypothesis by in vivo 
supplementation of recombinant TGF-β1 protein, which led to significantly reduced bone 
volume as well as decreased osteogenic marker gene expression (Figure 20A-C). We also 
showed that TGF-1 supplementation significantly increased plasma and muscle tissue PAI-1 
level, suggesting that the treatment is effective (Figure 20D&E). However, increased PAI-1 level 
did not correlate with increased bone volume, further suggesting that this negative feedback loop 
may be initiated from PAI-1, with TGF-β1 as the effector (Figure 20F). Glucocorticoids might 
directly affect TGF-β1 production independent of PAI-1 regulation as we and others have 
demonstrated [159], but the net effect of glucocorticoids on TGF-β1 is still downregulation of its 
expression (Figure 19D). 
To explore the underlying mechanism by which lowered TGF-1 level correlates with 
enhanced osteogenesis, we performed in vitro TGF-1 supplementation experiment using 
MDSCs, resident progenitor cells in muscle found both in mice and human [56, 81, 115]. Our 
results show that in vitro TGF-1 supplementation to MDSC cell culture almost completely 
blocks BMP-7-induced osteogenesis, suggesting that TGF-1 may play an inhibitory role on 
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MDSC osteogenesis (Figure 21C). MDSCs are the putative cell source responsible for HO 
formation [56, 82], and we have demonstrated here that a large number of PDGFRα positive 
cells, likely MDSCs, are present near the calcium deposits (Figure 21B), and participating in the 
process. We speculate that TGF-1 at physiological level could be the protective factor that 
inhibits osteogenic differentiation of MDSCs. However, when TGF-1 level is lowered under 
pathological conditions, muscle injury-induced BMP-7 upregulation could promote MDSC 
osteogenesis given that the protective factor(s) has been removed. In this study, we have 
demonstrated that glucocorticoid excess could be one of the reasons for lowered circulating 
TGF-1 level. There have also been some controversies regarding the role of TGF-β1 in DC/HO 
formation [99]. We speculate that this is due to the different pathways leading to bone formation, 
namely endochondral ossification and intramembranous ossification. Endochondral ossification 
progresses through a cartilaginous precursor stage which requires TGF-β signaling for 
chondrogenesis, whereas in cases of intramembranous ossification, TGF-β signaling exerts a 
direct inhibitory effect on stem cell osteogenesis [160]. It is also well known that TGF-β1 is a 
highly pleiotropic factor and has a paracrine effect in immune modulation [161]. The limitation 
of this study is that we have not tested the effect of lowered circulating TGF-β1 level on the 
immune system, which will be our future research direction. 
In summary, our study demonstrates that glucocorticoid excess impairs muscle 
regeneration and promotes DC/HO, and that TGF-β1 could be a key factor in modulating this 
process. We also tested this postulation in a mouse amputation model, where we did below-knee 
amputation to right leg of the animal and gave CTX injection to the calf muscle of left 
unamputated leg. We showed that under a stress condition, i.e. an amputation, CTX-induced 
muscle injury could easily result in DC/HO formation (3 out of 4 animals) within 2 weeks 
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(Figure 22). Plasma analysis of corticosterone, PAI-1, plasmin, and TGF-β1 at different time 
points will be the next step to test our hypothesis. These findings shed light on the understating 
of the pathogenesis of trauma-induced DC/HO. 
 
Figure 22. DC/HO formation in an amputation plus muscle injury mouse model 
               Representative microCT images showing DC/HO formation in #1,3,4 animals. 
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5.0  ROLE OF MUSLCE TISSUE DEATH IN HO PATHOGENESIS 
5.1 INTRODUCTION 
In order to preserve the residual limb function in blast-injured patients, the aggressive limb 
salvage strategy has been adopted [73]. This strategy generally advocates that amputation should 
be viewed as a reconstructive approach instead of an ablative one, and that residual limb length 
should be maintained as well as functional joint level. It has therefore often led to a final 
amputation level within zone of injury to preserve as much tissue as possible [106]. However, it 
has been noted that there is a significantly higher prevalence of HO in the residual limbs of 
combat-injured patients if a final amputation was performed within zone of injury compared to 
that was proximal to zone of injury [73]. This aggressive limb salvage strategy on one hand 
maximizes the function of residual limb, while on the other hand may increase the possibility of 
retaining nonviable tissue within the body [162]. Nonviable tissue may cause local inflammatory 
response that would trigger HO development. Indeed, it has been previously demonstrated that 
debridement of nonviable tissues diminishes HO formation [163]. In support of this notion, we 
have also found in our mouse blast-amputation model that minimized debridement led to a 
higher incidence of HO. However, the exact underlying mechanism for this observation is still 
unclear. Given that HO is always located distant from the injury zone/amputation site in our 
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mouse blast-amputation model, we hypothesized that dead muscle tissue elicits a systemic effect 
that facilitates HO formation. 
This current study aims to elucidate the role of dead muscle tissue in HO pathogenesis by 
implanting devitalized muscle tissue into healthy recipient mouse. Our laboratory has previously 
characterized the cytokine expression in human blast-traumatized skeletal muscle tissue obtained 
during the debridement of high-energy wartime extremity wounds, and found that dead muscle 
tissue elicited an strong immune response with increased cytokine expression related to fibrosis, 
especially elevated TGF-1 signal [164]. In this study, we hypothesized that immune response 
towards dead muscle tissue consumes TGF-1 locally resulting in lowered circulating TGF-1 
level, which will facilitate muscle injury-induced DC/HO formation. 
5.2 METHODS 
5.2.1 Devitalized muscle tissue muscle pouch implantation 
Muscle tissue was harvested from C57BL/6J mouse background and freeze-thawed for three 
times to achieve devitalization. Muscle pouch implantation was performed according to a 
previous described surgical procedure [165]. Briefly, animal was first anesthetized by Isoflurane 
inhalation, the inner thigh area was removed of hair and was sterilized broadly with ethanol. 
Then mouse was positioned onto the operative field facing up and a 0.5-cm longitudinal incision 
was made beneath the femoral artery. Muscle pouch was created by blunt dissection of muscle 
fibers in gracilis muscle. Next, a piece of 50 mg devitalized muscle tissue was placed into the 
exposed muscle pouch. Muscle fibers were then closed by tension, and skin was closed with 4-0 
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nylon sutures. Animal received a 3-day course of buprenorphine (0.05 mg/kg administered 
subcutaneously twice a day) for pain management. For muscle pouch implantation with CTX 
injection group, 100 L 10 M CTX was injected into biceps femoris muscle one day before 
devitalized muscle tissue muscle pouch implantation. Sham surgery was performed by cutting 
open the skin and exposing the muscle pouch but without devitalized muscle tissue implantation. 
5.2.2 Blood sample collection and analysis 
Blood sample was collected by cardiac puncture at the time of animal sacrifice. Mice were 
sacrificed at Day 3, Day 7, Day 14 time points with 4 mice in each of the following groups: 
untreated control group; CTX injection alone group; tissue implantation alone group; and CTX 
injection plus tissue implantation group. Blood was collected into the EDTA anticoagulant tube 
and centrifuged. Then, supernatant was collected and aliquoted for storage. Total TGF-1 level 
and total plasmin (PLG) level were determined using commercial ELISA kits purchased from 
abcam biotechnology company. 
5.2.3 Muscle tissue sample collection and analysis 
Muscle tissues were collected at Day 3, Day 7, Day 14 time points as described above. 
Specifically, gracilis muscle with the devitalized muscle tissue implant was collected together as 
the inner thigh muscle group which reflects the local response induced by the dead muscle tissue; 
whereas biceps femoris muscle was collected as the outer thigh muscle group which reflects the 
systemic response induced by the dead muscle tissue. Muscle tissue phosphorylated Smad3 level 
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and fibrinogen level were determined using commercial ELISA kits purchased from abcam 
biotechnology company. 
5.2.4 In vitro suppression of TGF- signaling 
To test the effect of suppressed TGF- signaling on MDSCs osteogenesis in vitro, MDSCs were 
maintained for three days in CTX-injured muscle tissue derived CM with or without the 
supplementation of 10 M TGF- type I receptor inhibitor SB431542 (abcam). On culture Day 3, 
MDSCs were collected for the measurement of TGF- signaling inhibition using a 
phosphorylated Smad3 ELISA kit as well as osteogenic marker gene expression by PCR. 
5.2.5 Histology and immunohistochemistry 
Muscle tissues were fixed in methanol and paraffin embedded, and routine H&E and Alizarin 
Red staining was performed on the tissue sections. Immunohistochemistry (IHC) was performed 
according to protocols described for the Vectastain Elite ABC Kit (Vector Laboratories, 
Burlingame, CA, USA). Primary antibody against PDGFRα was purchased from abcam 
biotechnology company. 
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5.3 RESULTS 
5.3.1 Dead muscle tissue promoted DC formation 
microCT imaging showed that combined devitalized muscle tissue implantation and CTX 
injection caused a significant amount of DC in 2 weeks while neither of them alone showed DC 
at implantation/injection sites (Figure 23). We also ruled out the effect of surgery on DC 
formation by showing that CTX injection plus sham surgery could not cause DC formation. 
Histology revealed that DC was always formed distant from the implant (Figure 24), indicating 
that dead muscle tissue did not calcify by itself but rather elicited a systemic effect that facilitates 
muscle injury-induced DC formation.  
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Figure 23. Dead muscle tissue promoted DC formation 
microCT image showed DC formation in (A) CTX injection group; (B) tissue implantation alone group; (C) CTX 
injection plus tissue implantation group; (D) CTX injection plus sham surgery group. Arrowheads indicate ectopic 
mineralization. 
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Figure 24. Location of DC relative to the implant 
(A) H&E staining showing the location of the implant (black square) relative to the DC (dashed black square). (B) 
Alizarin Red staining demonstrating the calcium deposition. Scale bar = 200 m 
5.3.2 Implantation of dead muscle tissue caused a decrease in circulating TGF-1 level 
To determine how dead muscle tissue would affect DC formation, we collected blood sample 
from mice with or without devitalized muscle tissue implantation, and measured the total TGF-
1 level and total plasmin level at Day 3, Day 7, Day 14 time points after implantation. 
Significantly decreased plasma levels of TGF-1 and plasmin were seen in mice with devitalized 
muscle tissue implant at later time points (Figure 25), which coincides with DC formation. We 
also confirmed the effect of the changes in circulating plasma protein levels of these proteins on 
muscle tissue by checking TGF-1 and plasmin target protein expression on outer thigh muscle. 
We showed that starting from Day 7 time point onwards, decreased phosphorylated Smad3 level 
and increased fibrinogen level were seen in mice with devitalized muscle tissue implant in outer 
thigh muscle (Figure 26). This change in plasma and tissue protein level was not observed in 
sham operated animals (Supplemental Figure 7&8). 
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Figure 25. Implantation of dead muscle tissue caused a decrease in circulating TGF-1 level 
Blood sample analysis of total TGF-1 and total PLG level in animal with or without dead muscle tissue 
implantation. (A&B) Day 3 time point. (C&D) Day 7 time point. (E&F) Day 14 time point.  
 78 
 
Figure 26. Effect of implantation of dead muscle tissue on muscle protein expression 
Muscle tissue sample analysis of phosphorylated Smad3 level and fibrinogen level in animal with or without dead 
muscle tissue implantation. (A-D) Day 3 time point. (E-H) Day 7 time point. (I-L) Day 14 time point.  
5.3.3 Local fibrotic response towards dead muscle tissue 
We also collected muscle tissue sample from the inner thigh which reflects the local response 
induced by the dead muscle tissue. We found significant higher phosphorylated Smad3 level and 
fibrinogen level in mice with devitalized muscle tissue implant in the inner thigh muscle starting 
from Day 3 time point onwards (Figure 26). Histology confirmed this finding by showing the 
positive staining of phosphorylated Smad2 and fibrin(ogen) surrounding the implant, as well as 
collagen deposition typical of a fibrotic response (Figure 27). PCR analysis of the inner thigh 
muscle tissue demonstrated increased collagen type I expression as well as decreased ALK5 
expression but not increased TGF-1 production (Figure 28A&B&C), suggesting that circulating 
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TGF-1 is consumed locally. In addition, slightly decreased TGF-1 production was found 
systemically (Figure 28E). 
 
Figure 27. Local fibrotic response towards the dead muscle tissue 
(A-E) Day 3 time point. (F-J) Day 7 time point. (K-O) Day 14 time point. H&E staining (A)(F)(K). Trichrome 
staining (B)(G)(L). IHC staining using isotype control antibody (C)(H)(M). IHC staining showing the expression of 
phosphorylated Smad2 (D)(I)(N). IHC staining showing the expression of fibrin(ogen) (E)(J)(O). 
 
 
Figure 28. PCR analysis of TGF-1 production 
PCR analysis of gene expression level of different genes related to TGF-1 signaling pathway at different time 
points. (A-D) Inner thigh muscle tissue. (E-H) Outer thigh muscle tissue.  
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5.3.4 Suppression of TGF- signaling potentiated MDSCs osteogenesis in vitro 
To test the effect of suppressed TGF- signaling on MDSCs osteogenesis in vitro, we performed 
in vitro TGF- signaling suppression experiment with a specific small molecular inhibitor of 
TGF- type I receptor SB431542. Our results first demonstrated that, inhibition of TGF- 
signaling by SB431542, although it did not affect Smad1 phosphorylation level (Figure 29A), 
significantly reduced Smad3 phosphorylation in MDSCs (Figure 29B). Accompanying the 
decreased phosphorylated Smad3 level, significant decrease in TGF-1 target gene PAI-1 
expression was observed (Figure 29C). At the same time, greatly enhanced osteogenic marker 
gene expression was found in the treated MDSCs (Figure 29D). These data collectively suggest 
that suppressed TGF- signaling potentiated MDSCs osteogenesis. Lastly, we demonstrated that 
PDGFRα positive MDSCs are present near the calcium deposits, suggesting the possibility that 
they are responsible for DC formation (Figure 30).  
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Figure 29. Suppressed TGF- signaling potentiated MDSCs osteogenesis in vitro 
(A) Phosphorylated Smad1 level measured by ELISA. (B) Phosphorylated Smad3 level measured by ELISA. (C) 
PCR analysis of TGF- target gene expression. (D) PCR analysis of osteogenic marker gene expression.  
 
 
Figure 30. MDSCs participated in DC formation 
IHC staining of PDGFRα positive MDSCs near the calcium deposits. CTL: without primary antibody.  
Scale bar = 200 m 
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5.4 DISCUSSION AND CONCLUSION 
In this study, we have attempted to address why different amputation levels would affect HO 
incidence. We hypothesized that dead muscle tissue not removed in zone of injury could promote 
HO formation. Our results support this hypothesis by showing that dead muscle tissue promotes 
DC formation in CTX-injured muscle tissue via a systemic effect, i.e., decreased levels of 
circulating TGF-1 and plasmin. We have previously shown that supplementation of TGF- 
inhibits osteogenesis in vivo and in vitro (Part 4). Here, we demonstrated that inhibition of TGF-
 signaling in vitro potentiated MDSCs osteogenesis, further confirming that TGF-1 may 
negatively regulate osteogenesis. Therefore, TGF-1 may act as a protective factor in vivo 
preventing pathological ectopic mineralization.  
We also demonstrated that implantation of dead muscle tissue induces a local fibrotic 
response, resulting in increased fibrin accumulation and increased TGF- signaling. Fibrin 
accumulation usually leads to subsequent fibrosis via TGF-1 signaling [166].  We speculate that 
reduced circulating TGF-1 level could be due to TGF-1 being consumed locally, given the 
constant rate of production we have demonstrated above (Figure 29). Fibrin accumulation may 
also cause local hyperfibrinolysis, therefore exhausting circulating plasmin. Decreased plasmin 
level is associated with DC/HO formation [112, 137], and is also associated with decreased 
circulating TGF-1 level as we have previously demonstrated (Part 4). Therefore, reduced 
circulating TGF-1 level could also be due to decreased plasmin level. 
The results reporting here could partially explain our previous finding that DC/HO in our 
blast-amputation model is always formed away from the amputation site. We speculate that local 
fibrosis caused by dead muscle tissue at the amputation site consumes circulating TGF-1 and 
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plasmin, therefore leading to systemically decreased TGF-1 and plasmin level, which will 
facilitate DC/HO formation in places distant from the zone of injury. 
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6.0  STUDY SUMMARY AND FUTURE DIRECTIONS 
This dissertation research aims to explore the mechanism for blast-trauma induced HO. We first 
showed that in a live animal blast trauma model that muscle trauma resulted from blast wave 
exposure is associated with HO formation. We largely ruled out the effects of other risk factors 
and showed that muscle trauma may be a major determinant of HO formation. We therefore next 
investigated the role of muscle injury in HO pathogenesis and demonstrated that BMP-7 is a key 
osteoinductive factor in injured muscle that facilitates HO formation. However, as it is well 
known that muscle injury alone cannot induce HO formation, the subsequent studies in the thesis 
work were focused on investigating the additional factors that could work in concert with muscle 
injury to cause HO formation. 
Recently, a novel notion has been proposed for the mechanism of ectopic mineralization: 
instead of the gain-of-function mutation (as in case of FOP), a loss-of-function cellular 
machinery could account for abnormal calcium deposition [108], namely the removal of the 
protective factors that normally prevent injured tissue from calcifying. We have focused on TGF-
1 as the target of protective factor since TGF- signaling usually antagonizes BMP signaling by 
competing for their down-stream co-Smad4 signaling component for nuclear signal transduction 
(Figure 31). We hypothesized that lowered circulating TGF-1 level would attenuate its 
inhibitory effect on BMP-7, thereby enhancing osteogenesis by allowing the BMP-7 signaling to 
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prevail. We further hypothesized that any pathological condition resulting in decreased 
circulating TGF-1 level may lead to DC/HO formation. 
 
Figure 31. Schematic of BMP signaling and TGF- signaling 
 
Cortisol stress response is next studied because excessive endogenous glucocorticoid 
production has always been found following severe trauma, which coincides with increased HO 
incidence. We have shown that high level of glucocorticoids lowers circulating TGF-1 level 
through alterations of protein level in the fibrinolytic system, which is relevant to the recent 
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finding that decreased plasmin level is associated with DC/HO formation [112]. Our results 
suggest that TGF-1 could be the plasmin target in regulating DC/HO formation via its influence 
on MDSCs, a possible cellular source for DC/HO. 
In the last part of the thesis work, we have demonstrated that the presence of dead muscle 
tissue promoted DC and also caused a decrease in circulating TGF-1 level, further supporting 
our hypothesis that any pathological condition resulting in decreased circulating TGF-1 level 
may lead to DC/HO formation. The effect reported here might be mediated via alterations of 
protein level in the fibrinolytic system, and might also be due to a direct fibrin-TGF-1 binding 
mechanism which depletes TGF-1 from circulation [167]. 
Decreased circulating TGF-1 level has been reported to be associated with calcification 
in the cardiovascular system, i.e., severely depressed serum TGF-1 level was found in advanced 
atherosclerosis featuring prominent calcification and ossification [168]. The pathogenesis of 
vascular calcification/ossification actually shares great similarity with muscle DC, in which 
tissue injury, inflammatory cell infiltration, progenitor cell osteogenic differentiation etc. are all 
integral parts of the disease [169, 170]. Interestingly, in atherosclerosis, BMP signaling also 
promotes vascular calcification, whereas TGF-1 protects against disease progression [171-173]. 
These data collectively suggest a universal role of BMP and TGF- signaling in pathological 
calcification/ossification. 
We report here a two-hit model for of blast trauma-induced HO and trauma-induced HO 
in general: muscle injury-induced upregulated BMP-7 level combined with pathological 
condition-induced downregulation of circulating TGF-1 level may result in DC/HO formation 
(Figure 32). 
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Figure 32. A schematic represents a two-hit model for blast trauma-induced HO 
 
The limitation of this study is that we did not delve deep into the immune system in 
regulating DC/HO formation, especially the role of macrophages in DC/HO pathogenesis. 
Macrophages were initially thought to be the source of the osteogenic factors, that are 
indispensable for initiating osteogenic process [28, 29, 56]. However, recently some studies 
pointed out that depletion of macrophages actually promotes DC/HO formation [108, 174]. We 
also discovered these discrepancies in this dissertation research. We showed that treatment with 
DEX (as an anti-inflammatory drug used to reduce macrophage number) treatment could either 
inhibit or promote ectopic mineralization (Part 3&4). The reason for these seemingly different 
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processes is still unclear. We speculate that this is due to the plasticity of the macrophage, 
namely the immunomodulatory activity from different macrophage subsets. Our preliminary data 
showed that DEX treatment greatly increased M2 macrophage number in CTX-injured muscle 
tissue, which coincided with increased BMP-7 expression (Figure 33). Therefore, we 
hypothesized that M2 macrophage could promote osteogenesis. Supplementation of TGF-1 in 
vivo, instead of reducing M2 macrophage number and suppressing osteogenesis, greatly 
increased M2 macrophage number with suppressed osteogenesis, thus contradicting our initial 
hypothesis (Figure 34). BMP-7 plays a role in inducing M2 macrophage differentiation [123]. 
However, supplementation of TGF-1 in vivo did not affect BMP-7 expression (Figure 33). 
Therefore, the inter-relationship between all these molecules still needs to be explored, which 
will be our future research directions. 
 
Figure 33. Participation of macrophage subsets in pathogenesis of DC/HO 
Western blot analysis of macrophage marker expression at different time points. (A) CTX treatment alone. (B) 
CTX+DEX co-treatment. Increased M2 macrophage number coincided with increased BMP-7 expression. iNOS: 
M1 macrophage marker; CD206: M2 macrophage marker. 
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Figure 34. Effects of TGF-1 supplementation in vivo on macrophages 
Increased CD206 expression was observed with TGF-1 supplementation upon CTX+DEX co-treatment.  (n=3) 
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APPENDIX A 
SUPPLEMENTAL FIGURES 
 
Figure 35. Supplemental figure 1. Morphology of bone formed in BMP-2 injection alone group and 
BMP-2/CTX co-injection group 
(A&B) H&E staining showing the presence of cartilage morphology at the day 7 time point in BMP-2-induced HO. 
(A) BMP-2 injection alone group. (B) BMP-2/CTX co-injection group. (C&D) H&E staining of decalcified tissue 
showing the bone morphology at the day 14 time point in BMP-2-induced HO. (C) BMP-2 injection alone group. (D) 
BMP-2/CTX co-injection group. Bar = 200 m. 
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Figure 36. Supplemental figure 2. Characterization of MDSCs 
(A) Surface marker profile of MDSCs analyzed by flow cytometry, including Sca-1, CD45, PDGFRα, CD90, CD31 
and CD34. Percent of MDSCs positive for the respective surface markers in total cell population. (B) Alizarin Red 
staining of calcium deposits in MDSCs growing in osteogenic medium (OM) and growth medium (GM). Bar = 200 
m. (C) BMP-2-induced osteogenesis in vitro. ALP gene expression in MDSCs was upregulated upon treatment 
with different concentrations of BMP-2 recombinant protein for 3 days. 
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Figure 37. Supplemental figure 3. Effect of different doses of DEX treatments on animal body weight 
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Figure 38. Supplemental figure 4. Corticosterone treatment stimulated ectopic mineralization 
 (A) microCT imaging illustrating ectopic mineralization formed in CTX+corticosterone co-treatment group at Day 
7 time point. Arrowheads indicate ectopic mineralization. micoCT imaging demonstrating that vehicle treatment 
alone did not result in ectopic mineralization. (B) microCT analysis of bone volume in 20 mg/kg and 40 mg/kg 
CTX+corticosterone co-treatment group at Day 7. (n=4) (C) microCT analysis of bone mineral density in in 20 
mg/kg and 40 mg/kg CTX+corticosterone co-treatment group at Day 7. (n=4) 
 94 
 
Figure 39. Supplemental figure 5. Characterization of HO formed in CTX+DEX co-treatment group  
An endochondral ossification process was found in 2 weeks as demonstrated by (A) H&E staining. (B) Safranin-O 
staining. (C) Alizarin Red staining. Upper panels: Bar = 500 m. Lower panels: Bar = 50 m. 
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Figure 40. Supplemental figure 6. TGF-1 supplementation inhibited DC formation at Day 14 time point 
(A) microCT imaging demonstrating reduced bone volume with TGF-1 supplementation for 7 days. Arrowheads 
indicate ectopic mineralization. (B) microCT analysis of bone volume and bone mineral density with and without 
TGF-1 supplementation (*, p < 0.05; n = 9). 
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Figure 41. Supplemental figure 7. Sham surgery did not affect plasma TGF-1 level 
Blood sample analysis of total TGF-1 and total PLG level in animal with CTX injection only (CTL) or CTX 
injection with sham surgery (Sham). (A&B) Day 3 time point. (C&D) Day 7 time point. (E&F) Day 14 time point.  
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Figure 42. Supplemental figure 8. Sham surgery did not affect muscle phosphorylated Smad3 level 
Muscle sample analysis of phosphorylated Smad3 level and fibrinogen level in animal with CTX injection only 
(CTL) or CTX injection with sham surgery (Sham). (A-D) Day 3 time point. (E-H) Day 7 time point. (I-L) Day 14 
time point.  
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APPENDIX B 
TABLES 
Table 1. PCR primer sequences 
 Forward (5’ to 3’) Reverse (5’ to 3’) 
Actin GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT 
Runx2 ATGATGACACTGCCACCTCTGAC ACTGCCTGGGGTCTGAAAAAGG 
OSX GATGGCGTCCTCTCTGCTT CGTATGGCTTCTTTGTGCCT 
 ALP ATCGGAACAACCTGACTGACCCTT ACCCTCATGATGTCCGTGGTCAAT 
BSP-1 TGCCCTCTGATCAGGACAAC  ATCCGACTGATCGGCACTCT  
OCN ACCATCTTTCTGCTCACTCTGCTG TATTGCCCTCCTGCTTGGACATGA 
BMPRIA ACCAGACGGTGTTAATGCGT CTCGATGAGCAATTGCAGGC 
BMPRIB CCCTCGGCCCAAGATCCTA CAACAGGCATTCCAGAGTCATC 
ACVR1 GTGGAAGATTACAAGCCACCA GGGTCTGAGAACCATCTGTTAGG 
TGF-1 CACCTGCAAGACCATCGACA CATAGTAGTCCGCTTCGGGC 
ALK5 CCTCGAGACAGGCCATTTGT GCCAGCTGACTGCTTTTCTG 
Col I TTCTCCTGGCAAAGACGGACTCAA AGGAAGCTGAAGTCATAACCGCCA 
PAI-1 TCTGGGAAAGGGTTCACTTTACC GACACGCCATAGGGAGAGAAG 
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